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 INTRODUCTION 
1.  PHARMACEUTICAL ANALYSIS  
(Sethi et al., 2003, Gurdeep R. Chatwal et al., 2007) 
Pharmaceutical Analysis comprises those procedures necessary to determine 
the identity, strength, quality and purity of pharmaceuticals. 
    It got two branches: 
Quality Control 
Quality Assurance 
Quality control 
  It is primarily designed to detect and correct defects or checking to 
demonstrate whether the anticipated results are complied with. 
Quality assurance 
It is oriented towards preventing defects from occurring. It is a managerial 
function which prevents problems by heading them off and by advising restraints and 
redirection at the proper time and level. 
1.1 ANALYTICAL CHEMISTRY                             ( Anjaneyulu et al., 2006)  
 A scientific discipline that develops and applies methods, instrument and 
strategies to obtain information on the composition and nature of matter in space and 
time. 
1.1.1 BRANCHES OF ANALYTICAL CHEMISTRY 
                        Biology 
                        Geology 
                        Chemistry 
                        Environmental Science 
          Material Science 
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          Social science 
   Medicine 
   Engineering 
   Physics 
   Agriculture 
1.1.2 DISCIPLINES OF ANALYTICAL CHEMISTRY 
There are two types of analysis. Those are as follows: 
Qualitative analysis 
Quantitative analysis     
1.1.2.1 Qualitative analysis 
This is practiced in order to establish the composition of naturally occur, 
artificially synthesized or manufactured substances. 
1.1.2.2 Quantitative analysis 
 There are several methods for quantitative analysis such methods are as 
mentioned below. 
 1.1.3 Chemical methods  
1.1.4 Titrimetric analysis 
The titrimetric methods are considered superior to gravimetric methods the 
analysis is similarly based on equivalent weight of one substance reacts quantitatively 
with the other. 
i. Acid-base titrations 
ii. Non-aqueous titrations 
iii. Redox titrations 
iv. Precipitation titrations 
v. Complexometric titrations 
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 1.1.5 Gravimetric analysis 
The method involves the conversion of the element or a radical to be 
determined into a pure stable compound, readily convertible into a form suitable for 
weighing. 
 1.1.6 Gasometric analysis 
 The gases like Cyclopropane, Carbondioxide, Nitrous oxide, Oxygen, Octyl 
nitrate, Nitrogen, Amylnitrate, Ethylene and Helium are determined by Gasometric 
analysis. The measurement of volume of gas is usually done by means of gas buretts 
(or) nitrometers. 
 1.1.7 Physicochemical methods 
These methods are mainly used for the measurement of certain physical 
properties and to determine the contents or composition of a substance. They are 
employed for the determination of trace concentrations of elements in preference to 
the sample. These are preferred due to their selectivity, simplicity, speed of analysis 
and accuracy than other methods. Most of the methods make use of standards having 
in the known amount of the constituents serves as the basis of comparison in the 
instrument. The changes in the properties of system detected by measurement of 
current, potential, electrical conductivity, specific rotation and refractive index.  
 1.1.8 Microbiological methods 
Many micro organisms produce within themselves in chemical substances, 
which when excreted, interfere with the growth or metabolism of micro organisms. 
Such compounds are known as antibiotics and need to be present in low 
concentrations to bring out the antibiotic action. Antibiotics are Chemotherapeutic 
agents. In micro biological methods comparison of the inhibition of the growth of the 
bacteria by a measured concentration of antibiotic which is to be examined is 
 4 
 
compared with the known concentration of the antibiotic standard preparation having   
known activity. Widely used methods are cup plate method and tube assay method. 
 1.1.9 Biological methods 
When the potency of the drug or its derivative cannot be properly determined 
by physical or chemical methods, and where it is possible to observe the biological 
effects of the drug on some type of living matter, the biological assays are carried out 
on the basis of such assays is to determine how much of sample gives the same 
biological effect as a given quantity of the standard preparation. The sample and 
standard tested under identical conditions in all respect. In a typical bio-assay,            
a stimulus is applied to a subject. The intensity of stimulus applied to a subject is 
referred to as the dose and is indicated by a weight or in terms of the concentration of 
the preparation. The application of a stimulus on a subject produces some observable 
effect and this is called the response. The response may be measured by the total 
weight or weight of some organ of the subject, blood sugar concentration, diameter of 
inhibition zone or by some other physiological symptoms. 
1.2 Factors Affecting the Choice of Analytical Methods    (Mendham et al., 2002) 
 Analytical techniques have different techniques of sophistication, sensitivity, 
selectivity requires different cost and time. Analyst should select best procedure for a 
given determination.    
 The form of chemical analysis required. 
 Difficulty arising from the nature of the substance 
 Feasible interference from apparatus of the material other than those of interest. 
 The concentration range which needs to be examined. 
 The precision required. 
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 The amenities available. 
 The time necessary for total analysis. 
 Analogous type of investigation performed.  
1.3 ANALYTICAL METHOD BASED ON MEASUREMENT OF  
PROPERTY                                                     (Gurdeep R. Chatwaal et al., 2007)  
S.No Physical property Analytical methods based on measurement 
of property 
1. Mass  Gravimetric  
2. Volume  Volumetric  
3. Electrical potential  
Electrical resistance 
Electrical current  
Electrical charge 
Potentiometry, Chronopotentiometry.  
Conductometry. 
 Polarography, Amperometry.  
 Columetry. 
4. Absorption of radiation  Spectrophotometry  
5. Emission of  radiation Emission spectroscopy, flame photometry, 
fluorescence, radio chemical methods 
6. Scattering of radiation  Turbidimetry, Nephelometry, Raman 
spectroscopy  
7. Refraction of radiation  Refractometry, Interferometry 
8. Rotation of radiation  Polarimetry, Optical rotatory dispersion 
9. Diffraction of radiation  X-ray electron diffraction methods  
10. Mass to charge ratio Mass spectrometry  
11. Thermal properties  Thermal conductivity and Enthalpy methods 
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1.4 APPLICATIONS OF ANALYTICAL CHEMISTRY 
                                                                                           (Anjaneyulu et al., 2006) 
1. Helping to save lives 
2. Consumer and Enviroment protection 
3. Farming support 
4. Crime prevention and detection 
5. Maintain fair play  
1.5 UV-SPECTROSCOPY                                   (Gurdeep R. Chatwal et al., 2007) 
Ultraviolet absorption spectra arise from transition of electrons within a 
molecule or an ion from a lower to higher electronic energy levels and the ultraviolet 
emission spectra arise from the reverse type of transition. For radiation to cause 
electronic excitation, it must be in the UV region of the electromagnetic spectrum. 
Ultraviolet region produces changes in the electronic energy of the molecule 
resulting from transitions of valence electrons in the molecule. Three different types 
of electrons are involved in organic molecules. They are follows,  
I. σ - electrons 
These electrons are involved in saturated bonds, such as those between 
carbons and hydrogen in paraffins. 
II. π - electrons 
These electrons are involved in unsaturated hydrocarbons. Typical compounds 
with π bonds are trienes and aromatic compounds. 
III.  n - electrons 
These are the electrons which are not involved in the bonding between atoms 
in molecules. Examples are organic compounds containing nitrogen, oxygen and 
halogens. 
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1.5.1 Electronic transitions                                                        (Sharma, 2007) 
 A molecule is excited by the absorption of energy (UV or Visible light). Its 
electrons are promoted from a bonding to an anti bonding orbital. 
i. The antibonding orbital which is associated with the excitation of σ electrons 
is called σ* anti bonding orbital. So σ       σ* transition take place when          
σ (sigma) electron is promoted to antibonding (σ*) orbital. It is represented as          
σ         σ* transition. 
ii. When a non-bonding electron gets promoted to an antibonding sigma orbital 
(σ*) then it represents n        σ* transition. 
iii. Similarly π    π* transition represents the promotion of π electrons to an   
antibonding π* orbital. 
iv. When an n- electron (non- bonding) is promoted to anti bonding π* orbital. It 
represents π         π* transition. 
1.5.2 Electronic excitation energies 
a) σ         σ* transition 
 The organic compounds in which all the valence shell electrons are involved 
in the formation of sigma bonds do not show absorption in the normal ultraviolet 
region, but occur in vacuum UV region (125-135 nm). 
E.g. Methane, Ethane, Propane, Cyclopropane. 
b) n         σ* transition 
This type of transition takes place in saturated compounds containing one 
hetero atom with unshared pair of electrons (n electrons). 
E.g. Alcohol, Ethers, Amines, etc. 
 Such transition require comparatively less energy than that required for                                                                       
σ         σ* transitions. 
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c) π         π* transition 
This type of transition occurs in the unsaturated centers of the molecule in 
compounds containing double or triple bonds and also in aromatics. The excitation of 
π electrons requires smaller energy and hence, transition of this type occurs at longer 
wavelength. 
E.g. Alkenes, Alkynes, Aromatic compounds, etc. 
d) n         π* transition 
In this type of transition an electron of unshared electron pair on hetero atom 
gets excited to π* antibonding orbital. This type of transition requires least amount of 
energy out of all the transitions. 
1.5.3 Laws of absorption                                      (Gurdeep R. Chatwal et al., 2007) 
There are two fundamental laws related to the absorption of monochromatic 
radiant energy by homogeneous transparent systems. These are Beer’s Law and 
Lambert’s Law. 
1.5.4 Beer’s law  
 The intensity of a beam of monochromatic light decreases exponentially with 
the increase in concentration of the absorbing substance arithmetically. 
I = I0e-kc 
Where,  I0 = intensity of incident light 
               I = Intensity of emerged light 
1.5.5 Lambert’s law 
 When a beam of light of light is allowed to pass through a transparent 
medium, the rate of decrease in the intensity of transmitted light with the thickness of 
medium is directly proportional to the intensity of the incident light. 
−

	∝  
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From these laws, the following empirical expression – Beer and Lambert’s Law 
A= Єct 
Where,  A= Absorbance or optical density or extinction co-efficient 
 Є = Molecular extinction co-efficient 
  c = Concentration of drug  
  t = Path length 
1.5.6 Limitations of Beer - Lambert’s law                             (Sharma, 2007) 
1. When different forms of the absorbing molecules are in equilibrium as in  
keto-enol tautomers. 
2. When fluorescence compounds are present. 
3. When solute and solvent forms complex through some sorts of association. 
1.5.7 Deviations from Beer’s law                      (Gurdeep R. Chatwal et al., 2007) 
From Beer’s law it follows that if we plot absorbance against concentration,    
a straight line passing through the origin should be obtained. But there is usually a 
deviation from a linear relationship between concentration and absorbance and an 
apparent failure of Beer’s law may ensure. Deviations from the law are reported as 
positive or negative according to whether the resultant curve is concave upwards or 
concave downwards. 
Deviations from Beer’s law can arise due to the following factors: 
I. Beer’s law will hold over a wide range of concentration provided the 
structure of the colored ion or of the colored non-electrolyte in the dissolved 
state does not change with concentration. If a colored solution is having a 
foreign substance whose ions do not react chemically with the colored 
components, its small concentration does not affect the light absorption, may 
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affect light absorption and may also alter the value of the extinction 
coefficient. 
II. Deviations may also occur due to the presence of impurities that fluoresce or 
absorb at the absorption wavelength. This interference introduces an error in 
the measurement of absorption of radiation penetrating the sample. 
III. Deviations may occur if monochromatic light is not used. 
IV. Deviations may occur if the width of slit is not proper and, therefore,            
it allows undesirable radiations to fall on the detector. These desirable 
radiations might be absorbed by impurities present in the sample which 
would cause an apparent change in the absorbance of the sample. 
V. Beer’s law cannot be applied to suspensions but the latter can be estimated 
calorimetrically after preparing a reference curve with known concentration. 
1.6 Choice of Solvent                                              (Gurudeep R Chatwal et al., 2007)     
Solvent used of ultraviolet spectroscopy should posses the following 
activities 
 Solvent under region of investigation should not absorb radiation 
 Polarity of solvent should not influence solute molecules. 
 High purity of solvent should be maintained. 
 
1.6.1 List of Common Solvents Used in UV-Spectroscopy      (Willam Kemp, 1996)            
 
S. No. SOLVENT CUT OFF WAVELENGTH (nm)  
1 Water 190 
2 Ethanol 205 
3 Methanol 210 
  
 
1.6.2 Solvent effects :
                  The 
solvent 
1. If absorbing substance is non polar, the effect of solvent is mainly 
determined by the refractive index of solvent
2. The dipole movement of the solvent is mainly responsible for the change 
in the position of absorption band
3. The diene systems are however independent of the solvent polarity
4. The absorption maximum for polar compounds is usually shifted with the 
change in the polarity of solvent.
1.7 Instrumentation 
                      (Anonymous.
4 Hexane
5 Cyclohexane
6 Diethyl ether
7 Chloroform
8 Carbon tetra chloride
9 DMF
10 Acetone
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absorption maximum is also influenced by the nature of 
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The following are the components of a typical UV–Visible spectrophotometer, 
a) Radiation source  
b) Monochromator 
c) Sample holder 
d) Detector 
e) Signal processor and readout 
1.8 Quantitative analysis                                                (Beckett and Stenlake, 2007) 
           The assay of an absorbing substance may be quickly carried out by preparing a 
solution in a transparent solvent and measuring its absorbance at a suitable 
wavelength. The wavelength normally selected is a wavelength of maximum 
absorption (λmax), where small errors in setting the wavelength scale have little effects 
on the measured absorbance. 
a. Assay of substances in single component samples 
           Quantitative analysis (assay of an absorbing substance) can be done using 
following methods. 
i. Use of a standard absorptivity values 
 This method can be used for estimation of drug from formulations or raw 
material, when reference standard not available. The use of standard A (1 %, 1 cm) 
value avoids the need to prepare a standard solution of the reference substance in 
order to determine its absorptivity, and is of advantage in situations where it is 
difficult or expensive to obtain a sample of the reference substance. 
ii. Use of calibration graph 
 In this procedure the absorbances of a number (typically 4-6) of standard 
solutions of the reference substance at concentrations encompassing the sample 
concentrations are measured and a calibration graph is constructed. The concentration 
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of the analyte in the sample solution is read from the graph as the concentration 
corresponding to the absorbance of the solution. Calibration data are essential if the 
absorbance has a non-linear relationship with concentration, or if the absorbance or 
linearity is dependent on the assay conditions. In certain visible spectrophotometric 
assays of colorless substances, based upon conversion to colored derivatives by 
heating the substance with one or more reagents, slight variation of assay conditions, 
e.g. pH, temperature and time of heating, may rise to a significant variation of 
absorbance, and experimentally derived calibration data are required for each set of 
samples. 
iii. Single or double point standardization 
          The single point procedure involves the measurement of the absorbance of a 
sample solution and of a standard solution of the reference substance. The standard 
and the sample solution are prepared in similar manner; ideally the concentration of 
the standard solution should be close to that of the sample solution. The concentration 
of the substance in the sample is calculated using following formula. 
                                    Ctest = A test × Cstd / Astd 
Where,
 
 
Ctest and Cstd are the concentration in the sample and standard solutions 
respectively.  
Atest and Astd are the absorbance of the sample and standard solutions 
respectively. 
 In double point standardization, the concentration of one of the standard 
solution is greater than that of the sample while the other standard solution has a 
lower concentration than the sample. The concentration of the substance in the sample 
solution is given by  
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                                  (Atest – Astd1)(Cstd1-Cstd2) +Cstd1 (Astd1-Astd2) 
                            Ctest  =              
                                Astd1-Astd2 
Where, 
Cstd is the concentration of the standard solution.  
Atest and Astd are the absorbance of the sample and standard solution 
respectively. Std1 and std2 are the more concentrated standard and less 
concentrated standard respectively. 
b. Assay of substances in multi component samples 
             The spectrophotometric assay of drugs rarely involves the measurement of 
absorbance of samples containing only one absorbing component. The pharmaceutical 
analyst frequently encounters the situation where the concentration of one or more 
substances is required in samples known to contain other absorbing substances which 
potentially interfere in the assay. Unwanted absorption from these sources is termed 
irrelevant absorption and if not removed, imparts systematic errors to the assay of the 
drug in the sample. A number of modifications to the simple spectrophotometric 
procedure for single-component samples are available to the analyst, which may 
eliminate certain sources of interferences and permit the accurate determination of 
one or all of the absorbing components. 
            The basis of all the spectrophotometric technique for multicomponent samples 
is the property that at all wavelengths: 
a) The absorbance of a solution is the sum of absorbances of the 
individual components. 
b) The measured absorbance is the difference between the total 
absorbance of the solution in the sample cell and that of the solution in 
the reference (blank) cell. 
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The determination of the multi-component samples can be done by using the 
following methods, 
i.       Simultaneous equations method. 
ii.       Absorbance ratio method (Q-Analysis). 
iii.       Geometric correction method. 
iv.       Orthogonal polynomial method. 
v.       Difference spectrophotometry. 
vi.       Derivative spectrophotometry. 
vii.       Chemical derivatisation. 
i. Simultaneous equation method 
If a sample contains two, absorbing drugs (X and Y) each of which absorbs at the λmax 
of the other as shown in Fig, it may be possible to determine both drugs by the 
technique of simultaneous equations (Vierodt’s method).   
  
 The Information required is:  
a)  The absorptivities of X at λ1 and λ2, ax1 and ax2, respectively  
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b) The absorptivities of Y at λ1 and λ2, ay1 and ay2, respectively  
c) The absorbance of the diluted sample at λ1 and λ2, A1 and A2 respectively. 
Let Cx and Cy, be the concentrations of X and Y respectively in the diluted sample. 
Two equations are constructed based upon the fact that at λ1 and λ2 the 
absorbance of the mixture is the sum of the individual absorbance’s of x and y, 
At λ1  A1 = ax1bcx + ay1bcy  ----------- (1) 
At λ2  A2 = ax2bcx + ay2bcy  ----------- (2) 
For measurement in 1cm cells, b = 1. 
 
Rearrange eq. (2) 
  Cy = A2– ax2cx 
      ay2 
Substituting for Cy in eq, (1) and rearranging gives 
  Cx = A2ay1 – A1ay2    (3) 
           ax2ay1 – ax1ay2 
and  Cy = A1ax2 – A2ax1    (4) 
           ax2ay1 – ax1ay2 
As an exercise we should derive modified equations containing a symbol (b) 
for path length, for application in situations where A1, and A2 are measured in cells 
other than 1 cm path length. 
 A2/A1   ay2/ay1 
 ax2/ax1          and  A2/A1  
Criteria for obtaining maximum precision, based upon absorbance ratios, have 
been suggested (Glenn, 1960) that place limits on the relative concentrations of the 
components of the mixture. The criteria are that the ratios should lie outside the range 
0.1-2.0 for the precise determination of Y and X respectively. These criteria are 
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satisfied only when the λmax of the two components are reasonably dissimilar. An 
additional criterion is that the two components do not interact chemically, thereby 
negating the initial assumption that the total absorbance is the sum of the individual 
absorbance. The additivity of the absorbance should always be confirmed in the 
development of a new application of this technique. The British Pharmacopoeia assay 
of quinine-related alkaloids and cinchonine-related alkaloids in cinchona bark is based 
upon this technique. 
ii. Absorbance ratio method 
           The absorbance ratio method is a modification of the simultaneous equations 
procedure. It depends on the property that, for a substance which obeys Beer’s law at 
all wavelengths, the ratio of absorbances at any two wavelengths is a constant value 
independent of concentration or pathlength. For example, two different dilutions of 
the same substance give the same absorbance ratio A1/A2, 2.0. In the USP, this ratio is 
referred to as a Q value. The British Pharmacopoeia also uses a ratio of absorbances at 
specified wavelengths in certain confirmatory tests of identity. For example, 
Cyanocobalamin exhibits three λmax at 278 nm, 361 nm and 550 nm. The A361/A550 is 
required to be 3.30 ± 0.15 and the A361/A278 to be 1.79 ± 0.09. 
iii. Geometric correction method 
             A number of mathematical correction procedures have been developed which 
reduce or eliminate the background irrelevant absorption that may be present in 
samples of biological origin. The simplest of these procedures is the three-point 
geometric procedure, which may be applied if the irrelevant absorption is linear at the 
three wavelengths selected. 
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iv. Orthogonal polynomial method 
            The technique of orthogonal polynomials is another mathematical correction 
procedure which involves more complex calculations than the three – point correction 
procedure. The basis of the method is that an absorption spectrum may be represented 
in terms of orthogonal functions as follows: 
 A (λ) = p0 P0 (λ) + p1 P1 (λ) + p2 P2 (λ) . . . pn Pn (λ) 
Where A denotes the absorbance at wavelength λ belonging to a set of n + 1 
equally spaced wavelengths at which the orthogonal polynomials,                        
P0(λ), P1(λ), P2(λ) . . . Pn(λ) are each defined. 
v. Area under the curve method 
              From the spectra obtained for calculating the simultaneous equation, the area 
under the curve were selected at a particular wavelength range for both the drugs were 
each drug  have its absorption. The “X” values of the drugs were determined at the 
selected AUC range. The “X” value is the ratio of area under the curve at the selected 
wavelength range with the concentration of the component in mg/ml. These “X” 
values were the mean of six independent determinations. A set of two simultaneous 
equations were obtained by using mean “X” values. And further calculations are 
carried out to obtain the concentration of each drug present in the sample. 
vi. Derivative spectroscopic method 
  This method involves the conversion of the normal spectrum into first, second 
or higher derivative spectrum. The transformation that occurs in the derivative 
spectrum is understood by reference to a Gaussian band which represents an ideal 
absorption band. 
  The first derivative (D1) spectra is a plot of the ratio of change of absorbance 
with wavelength  against wavelength, i.e., a plot of slope of the fundamental spectrum 
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against wavelength or a plot of  dA/ dλ Vs λ1. At λ2 and λ4, the maximum positive and 
maximum negative slope respectively in the D°. Spectrums correspond with 
maximum and minimum respectively in the D1 spectrum. The λmax at λ3 is a 
wavelength of zero slope and gives dA/d λ0, i.e., a cross-over point, in the D1               
spectrum . 
  The first order derivative spectrum of absorption band is characterized by a 
maximum, a minimum and a cross-over at a λmax of the absorption band. These 
spectral transformations confer two main advantages on derivative 
spectrophotometry. Firstly an even order spectrum is of narrower spectral band width 
than its fundamental spectrum. Derivative spectrum shows better resolution of 
overlapping bands than the fundamental spectrum and may permit the accurate 
determination of λmax of the individual bands. Secondly, derivative spectroscopy 
discriminates in favors of the substances of narrow spectral bandwidth against broad 
band width substances. 
1.9 INTRODUCTION TO HPLC METHODS OF ANALYSIS OF DRUGS IN 
COMBINED DOSAGE FORM      (Gurudeep R Chatwal et al., 2008)                                                                                          
 High performance liquid chromatography [HPLC] was developed in the late 
1960’s and 1970’s it is widely accepted separation technique for both sample analysis 
and purification in a variety of areas including the pharmaceutical, biotechnological, 
environmental polymer and food industries. 
HPLC instrumentation is made up of eight basic components they are          
mobile phase reservoir, solvent delivery system, sample introduction device, column, 
detector, waste reservoir, connective tubing and a computer, integrator (or) recorder.                
Chromatography is defined as a method of separating a mixture of                    
components into individual components through equilibrium distribution between two 
phases. Chromatography technique is based on the difference in the rate at which the 
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components of a mixture move through a porous medium (stationary phase) under the 
influence of some solvent or gas (mobile phase). 
    The chromatographic method of a separation in general involves the following 
steps: 
• Adsorption or retention of a substance or substance on the stationary phase. 
• Separation of the adsorbed substance by the mobile phase. 
• Recovery of the separated substance by a continuous flow of the mobile 
phase. The method being called elution. 
• Quantitative and qualitative analysis of the eluted substance 
1.9.1 Introduction to HPLC                                                        (Sharma, 2006)                                                                                                  
HPLC is a form of liquid chromatography to separate compounds that are              
dissolved in solution. HPLC instrument consists of four basic parts 
• The column 
• Detector 
• Injection system 
• Mobile-phase pump system 
            A schematic diagram of HPLC equipment 
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1.9.2 Principle of separation in HPLC                                      (Willard et al., 1986) 
The principle of separation in normal phase and reverse phase mode is the          
adsorption. When a mixture of components is introduced in to a HPLC column, they 
travel according to their relative affinities towards the stationary phase. The 
component which has more affinity towards the adsorbent travels slower. The 
components which have less affinity towards the stationary phase travel faster. Since 
no two components have the same affinity towards the stationary phase the 
components are separated. 
1.9.3 Modes of chromatography 
i. Normal phase mode 
ii. Reverse phase mode 
i. Normal phase chromatography 
In normal phase mode, the stationary phase (silica gel) is polar in nature and 
the mobile phase is non-polar. In this technique non-polar compounds travel faster 
and eluted first. The silica structure is saturated with silicon groups at the end and 
‘OH’ groups attached to silicon atoms are the active binding sites. 
ii. Reverse phase chromatography 
In reverse phase technique, a non polar stationary phase is used. The mobile 
phase is polar in nature hence polar components get eluted first and non-polar 
compounds are retained for a longer time. Since most of the drugs and pharmaceutical 
are polar in nature, they are not retained for a longer and eluted faster, which is 
advantageous. Different columns used are ODS (Octa DecylSilane) or C18, C8 and C4 
etc. 
1.9.4 Types of pumps 
• Reciprocating Piston Pumps 
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• Syringe Type Pump 
• Constant Pressure Pump 
 1.9.5 Columns for HPLC                                              (Willard et al., 1986)   
The columns most commonly used are made from precision bore polished 
stainless steel tubing; typical dimensions are 10-30 cm long and 4 (or) 5 mm internal 
diameter.  The stationary phase (or) packing is retained at each end by thin stainless 
steel frits with a mesh of 2 µm or less. The packing used in modern HPLC consist of 
small, rigid particles having a narrow particles size distribution. The types of column 
used in HPLC are 
• Standard columns 
• Radial compression columns 
• Narrow Bore columns 
• Short, fast columns 
• Guard columns and In-line filters 
1.9.6 Detectors                                                                 (Ashutoshkar, 2005)            
The main function of the detector in HPLC is to monitor the mobile phase 
coming out the column, which in turn emits electrical signals that are directly 
proportional to the characteristics either of the solute or the mobile phase.  
Basic detector requirements 
     An ideal LC detector should have the following properties: 
1. Low drift and noise level (particularly crucial in trace analysis). 
2. High sensitivity. 
3. Fast response. 
4. Wide linear dynamic range (this simplifies quantitation). 
5. Low dead volume (minimal peak broadening). 
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6. Cell design which eliminates remixing of the separated bands. 
7. Insensitivity to changes in type of solvent, flow rate, and temperature. 
8. Operational simplicity and reliability. 
9. It should be tunable so that detection can be optimized for different compounds. 
On-Line Detectors 
1. Refractive index. 
2. UV/Vis Fixed wavelength. 
3. UV/Vis Variable wavelength. 
4. UV/Vis Diode array. 
5. Fluorescence. 
6. Conductivity. 
7. Mass-spectrometric (LC/ MS). 
Off-Line Detector 
1. FTIR spiral disk monitor.    
1.10 VALIDATION 
(www.askaboutvalidation.com/forum/showthread.php?t=1175)                      
The word “Validation” means “Assessment” of validity or action of                                   
proving effectiveness. 
Types of validation   
The validation is divided into different types. They are, 
Prospective validation 
This method is employed when historical data of the Product is not available 
or is not sufficient and in process and finished product testing is not adequate to 
ensure reproducibility or high degree of compliance to product likely attributes. 
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Retrospective validation 
         This provides trend of comparative result (i.e.) review and evaluation of existing 
information for comparison when historical data is sufficient and readily available. 
 Concurrent validation 
Based on information generated during implementation of a system for this 
extensive testing and monitoring are performed as part of initial run of the method. 
  Re-validation 
Revalidation provides the evidence that changes in a process and are the process 
environment, introduced either intentionally or unintentionally, do not adversely 
affect process characteristic and product quality.  
There are two basic categories of revalidation. Revalidation in case of known 
change (including transfer of process from one company to another or from one site to 
another) Periodic revalidation carried out at scheduled intervals. 
 Reasons/ purpose of validation                                                         (Sethi, 2001) 
i. Setting standards of evaluation procedures. 
ii. Taking appropriate action in case of non-compliance. 
iii. Retrospective validation is useful for trend comparison of results compliance to 
cGMP/ cGLP.                                                                                                                                      
iv. Closer interaction with pharmacopoeia forum to address analytical problems. 
Enables scientist to communicate scientifically and effectively on technical 
matters. 
1.11   ANALYTICAL METHOD VALIDATION 
                                                  (Code Q2A;Q2B. ICH Guidelines1994 and 1996 ) 
Method validation is the process to confirm that the analytical procedure 
employed for a specific test is suitable for its intended use. Methods need to be 
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validated or revalidated. The International Conference of Harmonization (ICH) of 
technical requirements for the registration of pharmaceutical for human use has 
developed a consensus text on validation of analytical procedures. The document 
includes definition for eight validation characteristics. 
The parameters as defined by the ICH and by other organizations 
 
 Specificity  
 Selectivity 
 Precision  
 Repeatability  
 Intermediate precision  
 Reproducibility  
 Accuracy  
 Linearity  
 Range  
 Limit of detection  
 Limit of quantification  
 Robustness  
 Ruggedness  
SPECIFICITY  
Specificity is the ability to assess unequivocally the analyte in the presence of 
components which may be expected to present. An investigation of specificity should 
be conducted during the validation of identification tests, the determination of                 
impurities and assay.  
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ACCURACY  
  The accuracy of an analytical procedure expresses the closeness of              
agreement between the value which is accepted either as a conventional true value or 
on an accepted reference value and the value found.  
 Assay  
Assay of Active substances 
Assay of Medicinal products  
 Several methods are available to determine the accuracy   
a) Application of an analytical procedure to an analyte of known purity  
b) Comparision of the results of the proposed analytical procedure 
c) Application of the analytical procedure to synthetic mixtures 
 Impurity (Quantification) 
Accuracy should be assessed on sample spiked with known amounts of             
impurities. It should be clear how the individual or total impurities are to be                 
determined. 
Eg: weight/weight or area percent 
 PRECISION  
The precision of an analytical procedure expresses the closeness of the     
agreement between a series of measurements obtained from multiple sampling of 
same homogeneous sample under the prescribed conditions. Validation of tests for 
assay and for quantitative determination of impurities includes an investigation of 
precision. 
 Repeatability (intra- assay precision) 
Express the precision under small operating conditions over a short interval of 
time. It should be assessed using a minimum of nine determinations. 
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 Intermediate Precision 
The extent to which intermediate precision should be established depends on 
the circumstances under which the procedure is intended to be used. Typical           
validation to be studied includes days, analysts, equipments etc. 
 Reproducibility 
Reproducibility is assessed by means of an inter-laboratory trail.                    
Reproducibility should be considered in case of the standardization of an analytical 
procedure, for insistence inclusion of procedure in pharmacopoeias.  
 LINEARITY 
  Linearity of an analytical procedure is its ability (within a given range) to 
obtain test results which are directly proportional to the concentration (amount) of 
analyte sample. 
 RANGE 
Range of an analytical procedure is the interval between the upper and lower 
concentration of analyte in the sample including these concentrations for which it has 
been demonstrated that the analytical procedure has a suitable level of precision,           
accuracy and linearity.  
LIMIT OF DETECTION  
The detection limit is determined by the analysis of samples with known             
concentration of analyte and by establishing that minimum level at which the analyte 
can reliably detected. 
a. Based on visual evaluation 
b. Based on Signal-to-Noise ratio 
c.  Based on the standard deviation of the response and the slope 
• Based on the standard deviation of blank 
• Based on the calibration graph 
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 LIMIT OF QUANTIFICATION   
The quantification limit is generally determined by the analysis of samples with the 
known concentrations of analyte and by establishing the minimum value at which the 
analyte can be quantified with acceptable accuracy and precision 
a. Based on visual evaluation  
b. Based on Signal-to- Noise ratio 
c. Based on the standard deviation of the response and the slope 
• Based on the standard deviation of blank 
• Based on the calibration graph 
 ROBUSTNESS 
  The evaluation of robustness should be considered during the development 
phase and depends on the type of procedure under study. It shows the reliability of an 
analysis with respect to deliberate variations in the method parameters. 
 RUGGEDNESS 
  The united states of pharmacopoeia (USP) define ruggedness as the degree of 
reproducibility of test results obtained by the analysis of the same sample under a 
variety of normal test condition such as different labs, different analysis, different lots 
of reagents etc. Ruggedness is a measure of reproducibility of test results under 
normal expected operational conditions from laboratory to laboratory and from 
analyst to analyst. 
1.12 SYSTEM SUITABILITY PARAMETERS (Anonymous USP, 1995; Sethi 
2001) 
System suitability test are an integral part of gas and liquid chromatography. 
They are used to verify that the resolution and reproducibility of the chromatographic 
system are adequate for the analysis to be done. These tests are based on the concept 
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that the equipment, electronics, analytical operations and samples to be analysed 
constitute an integral system that can be evaluated as such. FDA guidelines on 
“Validation of chromatographic methods” the following acceptance limits are 
proposed as initial criteria. 
1) Capacity Factor (or) Retention (KA) 
The retention of a drug with a given packing material and eluent can be               
expressed as retention time or retention volume, but both of these are dependent on 
flow rate, column length and column diameter. The retention is best described as a 
column capacity ratio (K), which is independent of these factors. The column capacity 
ratio of a compound (A) is given as  
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2) Resolution (RS)
 
The resolution, Rs of two neighboring peaks is defined by the ratio of the            
distance between the two peak maxima. It is the difference between the retention 
times of two solutes divided by their average peak width. For baseline separation, the 
ideal value of Rs is 2.0. It is calculated by using the formula, 
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Where,  
Rt1 and Rt2 are the retention times of components 1 and 2  
W1 and W2 are peak widths of components 1 and 2  
3) Selectivity (α)
 
The selectivity (or separation factor) α, is a measure of relative retention of 
two components in a mixture. The ideal value of selectivity is 2. It can be calculated 
by using the formula,   
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Where, V0 is the void volume of the column and V2 and V1 are the retention  
volumes of the second and the first peak, respectively.  
4) Column efficiency 
Efficiency, (N) of a column is measured by the number of theoretical plates 
per meter. It is a measure of band spreading of a peak. Smaller the band spread, 
higher is the number of theoretical plates, indicating good column and system 
performance. Columns with N ranging from 5,000 to 100,000 plates/ meter are ideal 
for a good system. Efficiency is calculated by using the formula, 
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Where, Rt is the retention time and W is the peak width.  
5) Peak asymmetry factor (As) 
Peak asymmetry factor, As can be used as a criterion of column performance. 
The peak half width b of a peak at 10 % of the peak height, divided by the                 
corresponding front half width a gives the asymmetry factor. 
1.4 PHARMACEUTICAL STATISTICS 
 Linear regression 
  Linear regression is a statistical technique that defines the functional 
relationship between two variables by best-fitting straight line. Once a linear 
relationship has been shown to have a high probability by the value of the correlation 
coefficient ‘r’, then the best straight line through the data points has to be estimated. 
This can often be done by visual inspection of the calibration graph, but in many cases 
it is far more sensible to evaluate the best straight line by linear regression (the 
method of least squares) 
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The equation of straight line is  
y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable. 
         To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept 
‘c’ on the y axis are given by the following equation. 
             m =
		
	–	(
)	(
)
		
	–	
()
 
                              And 
C =
(Σy)(Σx)	–	(Σx)	(Σy)
N	Σx	– 	Σ(x)
 
 Correlation coefficient (r) 
It is a procedure commonly used to characterize quantitatively the relationship 
between variable. Correlation is related to linear regression. To establish whether 
there is a linear relationship between two variables x1 and y1, use Pearson’s  
correlation coefficient ‘r’.          
r = 	
nΣxy −	Σxy
{nΣx
 − (Σx)
nΣy
 − (Σy)
}/
 
  Where n is the number of data points. 
The value of ‘r’ must lie between +1 and -1, the nearer it is to +1, the greater 
the probability that a definite linear relationship exists between the variables x and y, 
values close to +1 indicate positive correlation and values close to -1 indicate negative 
correlation values of ‘r’ that tend towards zero indicate that x and y are not linearly 
related (they made be related in a non-linear fashion). 
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Standard deviation (SD) 
 It is commonly used in statistics as a measure of precision statistics and is more 
meaningful than is the average deviation. It may be thought of as a root-mean-square 
deviation of values from their average and is expressed mathematically as 
 
Where, 
S is standard deviation. 
If N is large (50 or more) then of course it is immaterial whether the term in the 
denomination is N -1 or N  
Σ       = sum 
x
      = Mean or arithmetic average. 
x -x 
 = deviation of a value from the mean 
N      = Number of observations 
  Percentage relative standard deviation (% RSD) 
It is also known as coefficient of variation (CV). It is defined as the standard 
deviation (S.D) expressed as the percentage of mean. 
                            C 100
x
S.DRSD  %or  V ×=
 
Where,  
S.D is the standard deviation, 
x
 = Mean or arithmetic average. 
 The variance is defined as S2 and is more important in statistics than S itself.  
However, the latter is much more commonly used with chemical data. 
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Standard error of mean (SE) 
 Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observations. It is mathematically         
expressed as  
                                             
n
S.D.S.E. =
           
  
Where,  
S.D = Standard deviation = number of observations. 
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2.  LITERATURE REVIEW 
2.1 DRUG PROFILE 
         (TheMerck Index 2006; http://www.rxlist.com/script/main/srchcont_ rxlist.asp?) 
LAFUTIDINE 
Molecular structure 
                                                     
Chemical name 
2-[(2-furylmethyl)sulphinyl]-N-((2Z)-4-{[4-(piperidin-1-ylmethyl)pyridin-2-
yl]oxy}but-2-en-1-yl)acetamide. 
Molecular formula 
C22H29N3O4 
Molecular weight   
431.55 g/mol 
Category 
 H2- Receptor antagonist, Anti- Secretory agent. 
Description 
           An off-white or white crystalline powder. 
Solubility 
           It is Freely soluble in DMF, Glacial Acetic Acid, soluble in Methanol, 
sparingly soluble in dehydrated ethanol. 
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Identification 
1) Melting Point 
Standard Value Observed Average Value* 
92.7- 94.9°C 92.5°C 
                    *Average of five observations 
2) IR Spectrum 
IR Spectrum of Lafutidine and interpreted and shown in the figure 1.   
Mechanism of Action 
Lafutidine an H2- Receptor antagonist inhibits gastric acid secretion not only in nights 
but also day time. 
Pharmacokinetics 
a) Distribution:  Lafutidine is 88% bound to plasma proteins, mostly albumin.           
b) Metabolism: Metabolised by CYP3A4(mainly), CYP2D6.   
Contraindications 
Lactation. 
Drug Interactions and precaution 
Constipation, hyperuricaemia, increase in total bilirubin, gynaecomastia, 
anorexia, hallucinations. 
 
 
 
 
 
 
 
  
2.2 DOMPERIDONE
                        (The Merck Index 2006; 
Molecular structure  
Chemical name 
5-chloro-1-[1-[3
4-yl]-1,3-dihydro-2H benzimidazole
Molecular formula 
C22H24ClN5O2 
Molecular weight 
425.91 g/mol 
Category 
 Dopamine antagonist
   Description 
White or almost white crystalline powder.
 Solubility 
Practically insoluble in water, slightly soluble in alcohol and methanol,
 soluble in DMF.
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-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]
-2-one.  
 
 
 
 
-piperidin-
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Identification 
1) Melting Point 
Standard Value Observed Average Value* 
    236 - 239°C            238.8°C 
                   *Average of five observations 
2) IR Spectrum 
IR Spectrum of Domperidone is compared with the standard values and 
principal peaks at a wave numbers were identified.  IR spectrum is shown in the 
figure 2. 
Storage Protected from light. 
Mechanism of Action and pharmacology 
Domperidone stimulates gastric muscle contraction by antagonizing the 
inhibitory effect of dopamine on post synaptic cholinergic neurons in the myenteric 
plexus. Dopamine effectively increases esophageal peristalisis and lower esophageal 
sphincter pressure, increases gastric motility and peristalisis, enhances gastroduodenal 
coordination and consequently facilitates gastric emptying. 
Pharmacokinetics 
a) Absorption 
 Peak plasma levels of Domperidone occur within 10-30 min after i.m 
injection and 30 min after oral administration.                                                                            
b) Metabolism 
Hydroxylation and Oxidative N-dealkylation 
Adverse effects  
Domperidone elevates serum prolactin levels, galactorrhoea, gynaecomastia, 
menstrual irregularities, thirst, nausea and diarrhoea. 
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2.3 REPORTED METHODS 
2.3.1 FOR LAFUTIDINE :  
1.  Wei- Dong Chen et al. (2006), Simple, sensitive and rapid LC-ESI-MS method 
for the quantification of Lafutidine in human plasma- Application to pharmacokinetic 
studies Lafutidine and internal standard were isolated from plasma samples by liquid- 
liquid extraction with diethyl ether using column C18 (150mm* 2.0mm, 5µm) at the 
flow rate of 0.2mL\min and with gradient elution using electro spray ionization 
detection source.  
2.  Lili Wu et al. (2009), Determination of Lafutidine in human plasma by high 
performance liquid chromatography – electro spray ionization mass spectrometry : 
Application to bio – equivalence study,  Determined the concentration of Lafutidine 
in human plasma by adding diazepam as internal standard and 1M NaoH solution to 
0.5 ml of plasma sample, Lafutidine was extracted from plasma with                    
Hexane : Isopropanol (95 : 5 % v\v) using v p ODS  C18 (250 * 2.0 mm) column with 
mobile phase  methanol : water (20mm CH3COONH4) in the ratio 80 : 20 % v/v and 
electro spray ionization interface and SIM mode detection. 
3. YE Xiang- fa et al. (2003), Determination of Lafutidine and its tablets by high 
performance liquid chromatography using ODS C18 column with mobile phase  
Methanol : 0.2M Ammonium acetate  solution : Triehylamine in the ratio 70 : 30: 0.1 
% v/v/v and the detection wavelength was set at 275 nm. 
4. Ding Hong-liang et al. (2009), Determination of Lafutidine by HPLC using C18 
column with mobile phase Methanol : 0.1M Sodium dihydrogen phosphate solution in 
the ratio 40 : 60 v/v with detection wave length set at 279 nm. 
5. Shangguan Ying – ying, et al. (2005), Determination of related substances in 
Lafutidine by RP-HPLC using C18 (4.6mm * 150mm, 5µm) column with mobile 
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phase Methanol : Acetonitrile : 0.02M  Phosphate buffer in the ratio 25 : 15 : 60 v/v/v 
adjusting the PH to 6.0 with Triethylamine at the flow rate 1 mL/min and the detection 
wavelength was set at 220 nm. 
6. Onodera et al. (1999), Gastro protective mechanism of Lafutidine, a novel anti 
ulcer drug with histamine H2 – receptor antagonist activity. Investigated the gastro 
protective activity of Lafutidine by examining the effect on ammonia induced change 
in trans- mucosal potential difference (PD), basal gastric mucosal blood flow (GMBF) 
and noxious agent induced cell damage. 
7. Shen Qian et al. (2007), Determination of Lafutidine concentration in human 
blood serum by HPLC using supercosil TM LC- 18-DB (4.6mm *250, 5µm) column 
with mobile phase Methanol : Sodium Acetate buffer in the ratio 1:2 at PH 4.5  using 
fluorescence detector at excitation wavelength at 285 nm and emission wavelength at 
313 nm. 
8.  Zheng Heng et al. (2008),   Determination of Lafutidine  in human plasma by 
HPLC-MS. Determined by taking 10µl of Ranolazine HCl (2.0 µg/mL internal 
standard) was  added to 0.5 ml of plasma. The plasma samples extracted with 5ml 
ether. The residue was dissolved in carbinol, 2 µl was injected in to ODS column with 
mobile phase as carbinol and the flow rate was set at 0.2 mL/min. 
9. Shimatani et al. (2006), Lafutidine, a newly developed anti-ulcer, elevates post 
prandial intragastric PH and increases plasma Calcitonin gene related peptide and 
Somatostatin concentrations in humans : Comparison with Famotidine. 
10. Sumitra et al. (2011), Reported Analytical method development and validation of 
Lafutidine in tablet dosage form by RP-HPLC, Determined using Hypersil silica C18 
(250 * 4.6, 5µ) column with mobile phase 0.02M Dihydrogen Potassium 
Orthophosphate and Acetonitrile in the ratio 30: 70 at a flow rate of 1 mL/min.  
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11. Zhen Yong et al. (2006), Reported determination of Lafutidine in serum with   
RP-HPLC, Determined by using c18 column with mobile phase Methanol and 0.005M 
Ammonium Dihydrogen phosphate at a flow rate of 1 mL/min, set a detection 
wavelength of 218 nm. 
12. Kouzuro Ikawa et al. Pharmacokinetic and pharmacodynamic properties of 
Lafutidine after post prandial oral administration in healthy subjects: Comparison 
with famotidine.  
2.3.2 FOR DOMPERIDONE 
1. Lakshmana Prabu et al, (2008), Simultaneous estimation of Esomeprazole and 
Domperidone by U.V Spectrophotometric method, estimated by using simultaneous 
eqution method using methanol as solvent the wavelengths selected are 301 nm and 
284 nm. 
2. Priti D. trivedi et al. (2010), Estimation of Esomeprazole and Domperidone by 
Absorption ratio method in pharmaceutical dosage form, estimated using methanol as 
solvent, Isobestic point was set at 290 nm. 
3. Ramesh Sawanth et al. (2010), Validated Spectrophotometric methods for 
simultaneous estimation of Paracetamol, Domperidone and Tramadol HCl in pure and 
tablet dosage form, Determined by using 0.1N NaoH. Method 1: Three wavelength 
spectrophotometry, the absorbances of sample solution was measured at 256 nm, 
289.6 nm, for the estimation of Paracetamol and Domperidone respectively and 
Tramadol HCl does not absorb at the wavelengths. Estimated  of Tramadol HCl is 
carried out at 218.4 nm. Method 2: Based on multiwavelength spectroscopic method. 
4. Ravikumar et al. (2006), Simultaneous estimation of Domperidone and 
Pantaprozole in solid dosage form by U.v spectrophotometry, Determined by  
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simultaneous equation method using cramels rule and  Absorption ratio method based 
on measurement absorptivity at  216, 287 and 290 nm. 
5. Patel et al. (2010), Development and validation of Derivative spectrophotometric 
method for simultaneous estimation of Domperidone and Rabeprazole Sodium in bulk 
and dosage form, determined by using first derivative spectrophotometry at 
wavelengths selected  at 253 , 266.4 nm  in sodium hydroxide solution. 
6. Sohan S. chitlange et al. (2010), Simultaneous spectrophotometric estimation of 
DexRabeprazole and Domperidone in capsule dosage form, Determined by using  
simultaneous equation at 258.5 and 286.5 nm wavelengths and multicomponent mode 
of analysis at 258 and 286.5 nm and area under curve at 263.5-253.5 and             
291.5-281.5 nm using methanolic HCl (0.1) as solvent. 
7. Karla Kapil et al. (2009), Spectrophotometric method for Simultaneous estimation 
of Paracetamol and Domperidone in tablet dosage formulation, Developed by 
simultaneous equation method with wavelengths selected at 250, 285 nm with 
methanol as solvent. 
8. Venkatesh et al. (2010), Spectrophotometric method for simultaneous estimation 
of Paracetamol and Domperidone in tablet dosage form, Domperidone and 
Paracetamol were estimated  by Simultaneous equation method at 284.5 nm and  
244.5 nm using 1N Glacial Acetic acid as solvent. 
9. Koujirou Yamamoto et al. (1988), Quantitative determination of Domperidone in 
rat plasma by HPLC with fluorescence detection, Determination of Domperidone in 
rat plasma involves Liquid- Liquid extraction followed by RP-HPLC with 
fluorometric detection at 282 nm for excitation and 328 nm for emission. 
10. Lakshmi Sivasubramanian et al. (2007), Simultaneous HPLC estmation of 
Omeprazole and Domperidone from tablets, Estimated by using Hypersil ODS C18 
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(150 * 4.6mm, 5µ) column  with mobile phase methanol : 0.1M Ammonium acetate 
(PH 9) in the ratio 60 : 40 v/v at a flow rate of 1 mL/min and the detection wavelength 
was set at 280 nm. 
11. Shozan Mondal et al. (2011), Development and validation of RP-HPLC method 
for the simultaneous estimation of Domperidone and Naproxen in tablet dosage form, 
Determined by using two LC-20 AT pump, SPD- 20A UV detector, SIL- 20A auto 
sampler and CTO-10 ASVP column oven with C18(250 * 4.6mm, 5µ) column and 
mobile phase was Phosphate buffer (PH adjusted to 3 with NaoH) : methanol in the 
ratio 30 : 70 v/v at a flow rate of 1 mL/min and detection wavelength was set at      
280 nm. 
12. Ahsanul Haque et al. (2011), Validated RP-HPLC method for estimation of 
Ranitidine HCl, Domperidone and naproxen in solid dosage form, Estimated in    
shim-pack CLC- ODS(250 * 4.6 mm, 5µ) column with mobile phase                    
0.1M Orthophosphoric acid solution (PH 3): Methanol in the ratio 35: 65 v/v at a flow 
rate of 1 mL/min and Uv detection was set at 280 nm. 
13. Sivakumar et al. (2007),  Development and validation of a RP-HPLC method for 
simultaneous determination of Domperidone and Pantoprazole in pharmaceutical 
dosage forms, Determined by using ODS analytical column with mobile phase as 
Methanol : Acetonitrile : Triehylamine solution ( PH 7 adjusted with 85% phosphoric 
acid ) in the ratio 20 : 33 : 47 v/v/v, at a flow rate of 1 mL/min and UV detection was 
set at 285 nm. 
14. Rakesh Kumar Singh et al. (2010), RP-HPLC method development and 
validation for simultaneous estimation of Ranitidine HCl and Domperidone in 
combined tablet dosage form, Determined efficient separation on phenomenax C18 
(250 * 4.6mm, 5µ) column using mobile phase Phosphate : Acetonitrile : Methanol in 
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the ratio 40 : 30 : 30 v/v/v in an isocratic mode of elution at a flow rate of 1.5 mL/min 
and detection wavelength was set at 210 nm. 
15. Vijaya Ratna et al. (2011), Reported RP-HPLC Method development and 
validation of Domperidone Maleate determined by using Luna C18 phenomenex         
(250 * 4.6mm,5µ) column with mobile phase methanol and water in the ratio            
50 : 50 v/v, the detection wavelength was set at 285 nm. 
16. Namitha et al. (2006), Quantification of Domperidone, Paracetamol, 
Esomeprazole and Lansoprazole in pharmaceutical dosage forms by RP-HPLC using 
superco c18 column with a mobile phase 0.01M Dipotassium hydrogen phosphate : 
Acetonitrile in the ratio 65: 35 v/v at a flow rate of 1 mL/min set at a detection 
wavelength of 285 nm. 
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3. Aim and plan of work 
The combination dosage form selected for the present study contains 
Lafutidine and Domperidone in solid oral dosage forms, recently this combination has 
been approved by DCGI (Drug Controller General India) 
In the view of the literature cited, method for estimation of Lafutidine and 
Domperidone individually and in combination with other drugs were reported, but no 
work is reported in the combination of both the drugs 
For UV method, 
1. Find the drugs solubility in various solvents 
2. To determine maximum absorbance and overlaid the spectrums 
3. Determining the standard absorbance for all selected wavelength for  
each drugs 
4. Development of simple, precise, accurate and sensitive 
 Simultaneous equations method 
 Area under curve method 
                  5.  Validation of developed methods as per ICH guidelines 
 For RP-HPLC method, 
1. A suitable mobile phase were selected for two drugs with proper  
resolution and short retention time 
2. Development of chromatogram with various concentration for each  
drug to determine range of concentrations 
3. Development of chromatogram in formulation 
4. Validation of the developed method  
  
 
 
Materials 
     & 
Methods
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                                     4. MATERIALS AND METHODS 
4.1. MATERIALS USED 
 4.1.1. DRUGS  
Lafutidine and Domperidone were generously gifted by Orchid 
Pharmaceuticals Pvt. Ltd., Chennai and the formulation containing Lafutidine 10 mg 
and Domperidone 30 mg tablets were purchased from a local pharmacy with the 
brand name LAFAXID- D. 
4.1.2. REAGENTS & CHEMICALS 
All  the  chemicals  used  were  of  analytical   grade  and  HPLC  grade 
procured  from  Qualigens,  India Ltd.   The chemicals used for the study were 
Acetonitrile (HPLC grade) 
Water (HPLC grade) 
Methanol (Analytical grade) and 
Ammonium Acetate (Analytical grade) 
4.1.3. Instruments Specifications 
a) Shimadzu AX – 200 digital balance: (Shimadzu instruction manual) 
Specifications 
Weighing capacity 200 gms 
Minimum display 0.1 mg 
Standard deviation ≤ 0.1 mg 
Operation temperature range 5 to 40° C 
 
b) Shimadzu UV – Visible spectrophotometer: (Shimadzu and Elico instruction 
manuals) 
Model : Shimadzu, UV-1700; Double beam UV - Visible spectrophotometer. 
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   ELICO SL – 210; Double beam UV - Visible spectrophotometer. 
Specification Shimadzu UV – 1700 Elico SL – 210 
Monochromator  Aberration- correcting 
concave blazed 
holographic grating 
Concave holographic 
grating with 1200 lines/ 
mm 
Detector Silicon photodiode Photodiode 
Stray Light 0.04% or less (220 nm; 
NAI 10g/ lt) 
0.04% or less (340 nm; 
NaNo2 50g/ lt). 
< 0.05% T at 220 nm with 
NAI  10g/ lt 
Measurement  
Wavelength range 
190 ~ 1100 nm 190 ~1100 nm 
Spectral Band width 1 nm or less                   
(190 to 900nm). 
1.8 nm 
Wave length 
Accuracy 
± 0.5 nm on broad 
automatic wavelength 
calibration mechanism. 
± 0.5 nm automatic 
wavelength calibration 
mechanism. 
Recording range Absorbance;                           
- 3.99 ~ 3.99 Abs 
Transmittance;                                                              
- 399 ~ 399% 
Absorbance; ± 3.000 Abs 
 
Photometric accuracy ± 0.004 Abs (at 1.0 Abs). 
± 0.002 Abs (at 0.5 Abs). 
± 0.005 Abs (at 1.0 Abs). 
± 0.010 Abs (at 0.5 Abs). 
Operating  
Temperature/ 
Humidity 
 
Temperature range; 15 to 
35˚C 
Humidity range; 
35 to 80% (15 to below 
35˚C) 
35 to 70% (30 to below 
35˚C) 
Temperature range; 15 to 
35˚C 
Humidity range; 
35 to 80% (15 to below 
35˚C) 
35 to 70% (30 to below 
35˚C) 
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c) Thermo Scientific Spectra High Performance Liquid Chromatography:  
Detector Specifications 
Light source Deuterium Arc lamp 
Measurement wavelength 
range 
190 to 700 nm 
Spectral Band Width 5 nm 
Wavelength Accuracy ± 1 nm 
Cell path length 10 nm 
Cell volume  20 µl 
Operating temperature range 4 to 35° C (39 to 104° F) 
Recording range 0.0001 to 4.000 AUFS 
Operating 
temperature/Humidity 4 to 35° C / 75 % 
 
Pump Specifications 
Pump type Double reciprocating plunger pump 
Pumping method Constant flow delivery and constant pressure delivery 
Suction filter 45 µm 
Line filter 5 µm mesh 
Operating 
temperature 
4 to 35° C (39 to 104° F) 
 
4) Sonica ultra sonic cleaner- model 2200 MH 
5) ELICO – pH meter model L1610 
6) Micropipette 
7) Melting point apparatus - Guna enterprises, Chennai. 
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4.2. METHODS EMPLOYED 
        The methods employed for the Simultaneous estimation of Lafutidine and 
Domperidone are 
4.2.1. UV Spectrophotometric method 
a) Simultaneous equation method 
b) Area under curve method 
Selection of solvent 
             The solubility of drugs was determined in a variety of solvents as per Indian 
pharmacopoeial standards. Solubility was carried out in non polar to polar solvents. 
The common solvent was found to be methanol for the analysis of Lafutidine and 
Domperidone for the proposed method. 
Preparation of standard stock solution 
 10 mg of  standard Lafutidine and Domperidone were  weighed and 
transferred into10 mL volumetric flasks separately and dissolved in methanol and 
made up to the volume with methanol. These solutions were observed to contain   
1000 µg mL-1. 
Selection of wavelengths for estimation and stability studies 
 The selection of wavelengths for the estimation Lafutidine and Domperidone  
a suitable diluted stock solution contain 10 µg mL-1 of each and the solutions were 
scanned between 200 and 400 nm by using methanol as blank. From the overlaid 
spectra, by the observation of spectral characteristics of Lafutidine and Domperidone  
the wavelengths selected were 273 nm and 287.5 nm respectively. The Stability was 
performed by measuring the absorbance of same solution at different time intervals. It 
was observed that Lafutidine and Domperidone in methanol were stable for more than 
4 hours at the selected wavelengths.  
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            For Area under the curve method, the area under the specified ranges for both 
the drugs was measured in area calculation mode. Wavelengths selected for 
Lafutidine is   276-271 nm and 291-282 nm for Domperidone. 
Preparation of calibration graph 
  Further diluted the standard stock solution to contain 80 µg mL-1  of Lafutidine 
and 240 µg mL-1 of Domperidone respectively. The  aliquots from  stock solution of   
Lafutidine (0.5 – 2. 5 ml of 80 µg mL-1)  and  Domperidone (0.5–2.5 ml of 240 µg 
mL-1) were  transferred  into a 10 mL  volumetric  flasks  and made  up to  the  
volume  with  methanol. The Absorbance of different concentrations were measured 
at 273 nm and 287.5 nm for Lafutidine and Domperidone. The calibration curve was 
plotted at their corresponding wavelengths. The two drugs, Lafutidine and  
Domperidone were  linear  with  the  concentration  range of  4-20 µg mL-1 and        
12-60 µg mL-1  respectively,  at  their  respective  wavelengths to the proposed 
methods. 
Quantification of formulation  
 Ten tablets of formulation LAFAXID- D (Containing Lafutidine 10 mg and 
Domperidone 30 mg) were weighed accurately. The average weight of tablets was 
found and powdered. The tablet  powder equivalent to 25 mg of Domperidone was  
weighed  and  transferred  into a 25 mL volumetric flask, added a minimum quantity 
of methanol to dissolve the substance by using ultra sonication for 15 minutes  and  
made  up  to  the  volume with methanol (1000 µg mL-1).  The content was filtered 
through Whatmann filter paper No. 41.  From the clear solution, further dilutions were 
made by diluting 3 mL to 25 mL with methanol in a 25 ml volumetric flask, further 
dilute 3 mL to 10 mL and obtained 36 µg mL-1 of Domperidone and 12 µg mL-1 
Lafutidine respectively. The absorbance measurements were made 5 times for the 
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formulation at 273 nm and 287.5 nm. From the absorptivity values of Lafutidine and 
Domperidone at 273 nm and 287.5 nm, the amount of Lafutidine and Domperidone 
could be determined by using Simultaneous equation method. 
  The area measurements were made for the same dilutions in area calculation 
mode at the selected wavelengths between 276 and 271 nm and 291 and 282 nm. The 
amount was calculated by using area under curve method.    
Recovery studies 
 The recovery experiment was done by adding  known concentrations of 
Lafutidine and Domperidone raw material to the 50% preanalyzed formulation.  
Standard  Lafutidine and  Domperidone  in  the  range  of  80%, 100% and 120% is 
added to the 50% preanalyzed formulation into a series of 10 mL volumetric  flasks,  
and diluted with methanol and the contents were sonicated for 15 minutes  then the 
solution was made up to mark with methanol.  After sonication, the solutions were 
filtered through Whatmann filter paper No. 41. The absorbances of   the resulting   
solutions were measured at their selected wavelengths
 
for the determination of  
Lafutidine and  Domperidone. The amount of each drug recovered from the 
formulation was calculated by Simultaneous equation method and Area under curve 
method. The procedure was repeated for three times.  
Validation of developed method  
Linearity 
 A calibration curve was plotted between concentration and absorbance. 
Lafutidine was found linear with the concentration range of 4-20 µg mL-1 and 
Domperidone showed the linearity in the range of 12-60 µg mL-1 at selected 
wavelengths for both the methods. 
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Accuracy (Recovery studies) 
 Accuracy of the method was confirmed by recovery studies. To the 
preanalyzed  formulation,  a  known  quantity  of  raw  materials  of  Lafutidine and  
Domperidone  were  added  and  the  procedure  was followed  as  per  the  analysis  
of  formulation. The amount of each drug recovered was calculated. This procedure 
was repeated for three times for each concentration. The % RSD was calculated. 
Precision 
            The  repeatability  of  the method was confirmed by the analysis of 
formulation  and repeated  for  5 times  with  the  same  concentration. The amount of   
each drug present in the tablet formulation was calculated. The % RSD was 
calculated. The  intermediate  precision  of  the  method  was  confirmed  by intraday  
and  inter day  analysis,  i.e.,  the analysis  of  formulation was repeated  three times  
in  the  same  day  and  on  three  consecutive days.  The amount of drugs was 
determined and % RSD also calculated.     
Ruggedness  
 Ruggedness of the method was confirmed by the analysis of formulation and 
performed by the different analysts and with different instruments. The amount and  
% RSD were calculated. 
LOD and LOQ 
The linearity study was carried out for six times. The LOD and LOQ were 
calculated by using the average of slope and standard deviation of intercept. 
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4.2.3 RP-HPLC METHOD DEVELOPMENT AND OPTIMIZATION OF 
CHROMATOGRAPHIC CONDITIONS 
Selection of mobile phase and λmax 
 Solutions of  Lafutidine and  Domperidone (10 µg mL-1) were  prepared  in  
the mobile  phase  [Methanol : 0.5% Ammonium Acetate Buffer  (85:15 v/v)] and  
scanned  in  the  UV region  of  200-400 nm  and  recorded  the spectrums. It was 
found that the two drugs have marked absorbance at 220 nm and can be effectively 
applied for estimation of two drugs without interference. Therefore  220 nm  was  
selected  as detection wavelength for estimation of  two  drugs by RP-HPLC  method  
with  an  Isocratic elution  technique. 
Stability of sample solutions  
 Solutions  of  Lafutidine and  Domperidone  (10 µg mL-1) absorbance  were  
checked  for  their  stability at  220 nm and  it  was  found  that  two drugs  were  
stable  for  approximately  three  hours. 
OPTIMIZATION OF CHROMATOGRAPHIC CONDITIONS 
Initial separation conditions  
      The  following  chromatographic  conditions  were  preset  initially  to  get  better 
resolution  of  Lafutidine and Domperidone. 
Mode of operation - Isocratic 
Stationary phase - Intersil ODS-3V (150 mm × 4.6 mm i.d. 5µ) 
column 
Mobile phase - Methanol : 0.5% Ammonium acetate buffer  
Proportion of mobile phase - 50 : 50% v/v 
Detection wavelength - 220 nm 
Flow rate - 1 mL/min 
Temperature - Ambient 
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Sample load - 20 µL 
Operating pressure -  2000 psi 
Method - External Standard Calibration method. 
The  mobile  phase  was  primarily  allowed  to  run  for  30  minutes  to  
record a steady baseline. Mixture of Solutions of   Lafutidine and Domperidone were 
injected and the respective chromatogram was recorded.  It was found that both 
Lafutidine and Domperidone were splitted, for this reason different ratios of mobile 
phase were attempted to obtain good chromatogram with acceptable system suitability 
parameters. 
Selection of mobile phase 
  A mobile phase contains Methanol and 0.5% Ammonium acetate buffer was 
selected. 
The ratio of the mobile phase is 
S. No Mobile phase Observation 
1 
Methanol : 0.5 % Ammonium 
Acetate Buffer (85:15 v/v) 
Both the Lafutidine and Domperidone 
were eluted with sharp peak 
            
Optimized chromatographic conditions 
 The following optimized conditions were employed for the analysis of 
Lafutidine and Domperidone by Isocratic RP-HPLC method. 
Mode of operation -  Isocratic 
Stationary phase -   Intersil ODS-3V (150 mm × 4.6 mm i.d. 5µ) 
column 
Mobile phase - Methanol :0.5% Ammonium Acetate buffer   
 55 
 
Proportion of mobile phase     - 85 : 15% v/v 
Detection wavelength    - 220 nm 
Flow rate - 1 mL/min 
Temperature - Ambient 
Sample load - 20 µL 
Operating pressure - 2000 psi 
Method - External Standard Calibration method. 
Preparation of standard Lafutidine solution 
 50 mg of  standard Lafutidine was weighed accurately and transferred into a 
100 mL  volumetric  flask  and  dissolved  in  methanol, after dissolution the volume 
was  made  up  to the  mark  with  methanol (500 µg mL-1). Further dilution was made 
by pipetting 10 mL of standard stock into a 100 mL to acquire 50 µg mL-1 solution. 
Preparation of standard Domperidone solution 
 190.89 mg  of  standard Domperidone equivalent to 150 mg of Domperidone 
Maleate  was  weighed  accurately  and  transferred into a 100 mL volumetric  flask  
and  dissolved  in  methanol, after dissolution the volume was made up to the  mark  
with  methanol (1500 µg mL-1).  Further dilution was made by pipetting 10 mL of 
standard stock into a 100 mL to acquire 150 µg mL-1 solution. 
Preparation of Calibration graph 
                             In  this progression,  the  aliquots  of  stock  solution  of  Lafutidine        
(0.7 – 1.3 mL of 500 µg mL-1) and  Domperidone (0.7 – 1.3 mL of 1500 µg mL-1)    
were  transferred  into a 10 ml  volumetric  flasks  and  made up  to  the  mark  with  
mobile  phase, and the solutions  contains  35, 40, 45, 50, 55, 60 and  65 µg mL-1 of  
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Lafutidine and 105, 120, 135, 150, 165, 180 and 195 µg mL-1 Domperidone.  The 
solutions were injected and the chromatograms were recorded at 220 nm.  The above 
concentration range was found to be linear and obeys Beer’s law. The procedure was 
repeated for six times.  The peak areas were plotted against concentration and the 
calibration curve was constructed. 
Estimation of Lafutidine and Domperidone in tablet formulation 
 Estimation of Lafutidine and Domperidone in tablet formulation by RP-HPLC 
was carried out in three levels using optimized chromatographic conditions. Ten 
tablets of formulation (LAFAXID-D) were weighed accurately. The average weight 
of tablets was found and powdered. The tablet powder equivalent to 50 mg of 
Lafutidine was weighed  and  transferred  into a 100 mL volumetric flask and  added  
a  minimum  quantity  of  methanol  to  dissolve  the  substance  and  the content was 
sonicated for 15 minutes, and made up to the volume with methanol then filtered  
through  Whatmann  filter  paper No. 41.  
Assay Procedure  
From the above clear solution, the aliquots of 0.8, 1.0, 1.2 mL were taken in to three 
separate 10 mL flasks and made the volume with mobile phase and obtained 40, 50, 
60 µg mL-1 solution of Lafutidine and 120, 150, 180 µg mL-1 of Domperidone. A 
steady base line was recorded with optimized chromatographic conditions. After the  
stabilization  of   base  line for 30 minutes,  three  test  solutions of  formulation  were  
injected  and recorded  the  chromatograms.  The concentration of each test solution 
was determined by using slope and intercept values from the calibration graph. 
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Recovery Experiments  
a) Preparation of Lafutidine and Domperidone raw material stock solution 
      100, 300 mg of Lafutidine and Domperidone were weighed separately and transfer 
in to a 100 mL standard flask and made up the volume with Methanol and kept aside. 
b) Procedure 
           To each 1 mL of  preanalyzed formulation solution (50 µg mL-1 of Lafutidine 
and  150 µg mL-1)  added  0.5, 1, 1.5 mL   of  raw material stock solution into 10mL 
volumetric  flasks  and  made  up  to  the  mark  with mobile phase. The procedure 
was repeated as per analysis of formulation. The quantity of drug recovered was  
calculated  by  using  slope  and  intercept  values  from  the  calibration  graph. 
System suitability studies 
           The   system   suitability   studies conceded as per ICH guidelines and USP. 
The   parameters  like  capacity factor,  tailing factor,  asymmetry factor  and  number 
of  theoretical  plate  and  resolution  were  calculated. 
Mobile Phase 
The   mobile phase used for RP-HPLC was Methanol : 0.5 % Ammonium 
Acetate buffer (85 : 15 v/v) 
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5. RESULTS AND DISCUSSION 
  Estimation of multiple drug formulations have advantage that the methods are 
less time consuming and usage of solvent is minimized. Two simple, rapid, precise 
and accurate spectrophotometric  methods  and  an  isocratic  RP-HPLC  method  
were developed and validated for the  estimation  of  Lafutidine and  Domperidone  in  
pure form and in combined tablet dosage form. The raw materials were generously 
gifted by Orchid Pharmaceuticals Pvt. Ltd. and confirmed by Melting point and I.R 
spectrum which are shown in Figure 1 and 2. The methods employed are  
 UV Spectrophotometric methods 
  Simultaneous Equation method 
                  Area Under Curve method 
 RP-HPLC method 
5.1. SIMULTANEOUS EQUATION METHOD 
 The solubility of Lafutidine and Domperidone was determined as per Indian 
Pharmacopoeia. The numeral polar and non – polar solvents were attempted to 
dissolve the drugs. From the solubility profile methanol was chosen as a common 
solvent for the estimation of Lafutidine and Domperidone. The solubility data is in 
Table 1 for Lafutidine and Domperidone. 
         The  sample  solutions of 10 µg mL-1 of Lafutidine and Domperidone in 
methanol  prepared  individually  and  the  solutions  were  scanned  in  UV region in 
the wavelength range from 200 to 400 nm by using methanol as blank. The individual 
and overlaid spectra of Lafutidine and Domperidone were recorded as shown in 
Figure 3, 4 and 5. From the spectrum, 273 nm was chosen as λmax of Lafutidine and 
287.5 nm was chosen as λmax of Domperidone, these two wavelengths employed for 
Simultaneous estimation of Lafutidine and Domperidone respectively. Different 
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aliquots of Lafutidine in methanol were prepared in the concentration range of            
4 -20 µg mL-1. The absorbances of solutions were measured at 273 nm and 287.5 nm. 
The calibration curve was plotted using concentration against absorbance. The 
calibration graph at 273 and 287.5 nm is shown in Figure 6 and 7. Different aliquots 
of Domperidone in methanol were prepared in the concentration range of                  
12-60 µg mL-1. The absorbances of these solutions were measured at 273 nm and 
287.5 nm. The calibration graphs were plotted and are shown in Figure 8 and 9. The 
preparation of calibration curve was repeated for five times for each drug at their 
selective wavelengths. The optical parameters like, Sandell’s sensitivity, Molar 
absorptivity, Correlation coefficient, Slope, Intercept, LOD, LOQ and Standard error 
were calculated. The correlation coefficient for the two drugs was found to be above 
0.999. This indicates that all the drugs obey Beer’s law in the selected concentration 
range.  Hence the concentrations were found to be linear. The optical characteristics 
of two drugs at their selective wavelengths are shown in Table 2 for Lafutidine and 
Table 3 for Domperidone. The formulation LAFAXID-D tablets containing 10 mg of 
Lafutidine and 30 mg of Domperidone was selected for analysis. The nominal 
concentration of Domperidone from the linearity (36 µg mL-1) was prepared and also 
contains (12 µg mL-1) of Lafutidine, the absorbances of the solution were measured at 
their respective wavelengths. The percentage label claim present in tablet formulation 
was found to be 99.49 ± 1.874 and 100.36 ± 1.06 for Lafutidine and Domperidone, 
respectively. The  amount  present in tablet formulation  was  in  good  concord  with  
the  label  claim  and  the % RSD values were found to be 1.1588 and  0.4664  for  
Lafutidine and  Domperidone, respectively. The low % RSD values indicate that the 
method has good precision. The results of analysis are shown in Table 4. 
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 Further the precision of the method was confirmed by Intraday and Inter day 
analysis. The analysis of formulation was carried out for three times in the same day 
and one time in the three consecutive days. The % RSD value of  intraday  and  inter 
day  analysis  were  found  to be  and 0.0510 and 0.8245  for  Lafutidine, 0.6245  and 
0.6468  for Domperidone. The results of analysis are shown in Table 5. The  results  
showed  that  the  precision  of  the  method  was  confirmed. 
 The developed method was validated for Ruggedness. It  refers  to  the  
specific  of  one  lab  to multiple  days  which may include multiple analysts, multiple 
instruments and different sources of reagents and so on. In the present work it was 
confirmed by different analysts and different instruments. The % RSD value by 
analyst 1 and  analyst 2  were  found  to be  0.9419  and  0.3133  for  Lafutidine and 
0.2872 and 0.2838 for Domperidone,  respectively. The low % RSD values indicate 
that the developed method was more rugged. The results are shown in Table 6 & 7. 
The % RSD values by instrument 1 and instrument 2 was found to be 0.9566 and 
0.8206 for Lafutidine and 0.4443 and 0.3248 for Domperidone. The results are shown 
in Table 8 & 9.   
               The accuracy of the method was performed by recovery studies. To the 50 % 
preanalysed formulation, a known quantity of Lafutidine and Domperidone raw 
material solutions were added at different levels. The absorbance of the solutions was 
measured and the percentage recovery was calculated.  The  percentage  recovery  
was  found  to  be  in  the  range of 98.125-98.67 % for Lafutidine and 99.32-99.68 %  
for Domperidone. The % RSD values were 0.2807 and 0.2032 for Lafutidine and 
Domperidone. These low % RSD value for the two drugs indicates that this method is 
very accurate. The recovery data is shown in Table 10.  
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5.2 AREA UNDER THE CURVE METHOD 
            The solutions containing 10 µg mL-1 of Lafutidine and Domperidone in 
methanol were prepared individually and the solutions were scanned in UV region in 
the wavelength range from 400-200 nm by using methanol as blank. From the 
spectrum, 276-271 nm was chosen as the area range for Lafutidine and 291-282 nm 
was chosen as the area range for Domperidone. This two wave length ranges were 
used for the estimation of Lafutidine and Domperidone by area under curve method. 
            Aliquots of Lafutidine and Domperidone in methanol were prepared in the 
concentration range of 4-20 µg mL-1and 12-60 µg mL-1. The area of the solutions was 
measured at 276-271 nm for Lafutidine and 291-282 nm for Domperidone. The 
calibration curve was plotted using area against concentration. The calibration curve 
at 276-271 nm and 291-282 nm for Lafutidine are shown in Figure 10 and 11. The 
calibration curve of Domperidone at 276-271 and 291-282nm were plotted and are 
shown in Figure 12 and 13. The preparation of calibration curve was repeated for six 
times for each drug at their selective wavelengths. The optical parameters like, 
Sandell’s sensitivity, Molar absorptivity, Correlation coefficient, Slope, Intercept, 
LOD, LOQ and Standard error were calculated. The Correlation coefficient for both 
the drugs was found to be around 0.999. This indicates that both the drugs obey 
Beer’s law and they were linear at the selected concentration range. The optical 
characteristics of two drugs at their selective wavelengths are shown in   Table 11 & 
12. The concentration of solution containing both Lafutidine and Domperidone 36 µg 
mL-1 was prepared and the area of the solutions was measured at their respective 
wavelength ranges. The percentage purity of formulation     LAFAXID-D was found 
to be 99.49 ± 1.87 and 100.36 ± 1.06 for Lafutidine and Domperidone, respectively. 
The amount present in formulation was in good concord with the label claim and the 
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% RSD values were found to be 0.8822 and 0.41407 for Lafutidine and Domperidone, 
respectively. The results of analysis were shown in Table 13. The low % RSD value 
indicates that the method was highly precise.  
.        Further, the precision of the method was confirmed by Intraday and Interday 
analysis. The analysis of formulation was carried out for three times in the same day 
and one time in the three consecutive days. The % RSD value of intraday and         
inter day analysis were found to be 0.8658 and 0.7124 for Lafutidine, 0.2456 and 
0.6629 for Domperidone. The results of analysis are shown in Table 14. The results 
revealed that the method was highly precise. 
 The developed method was validated for Ruggedness. It refers to the 
specificity of one lab to multiple days which may include different analysts, different 
instruments and different sources of reagents and so on. In the present work it was 
confirmed by different analysts and different instruments. The % RSD value by 
analyst 1 and analyst 2 was found to be 0.4815 and 0.8316 for Lafutidine and 0.3057 
and 1.1126 for Domperidone, respectively. The low % RSD value indicates that the 
developed method was more rugged. The results were shown in Table 15 & 16.      
The % RSD values by instrument 1 and instrument 2 was found to be 1.0123 and 
0.5407 for Lafutidine and 0.3682 and 0.7037 for Domperidone. The low % RSD 
value indicates that the developed method was more rugged. The results are shown in 
Table 17 & 18.  
            The accuracy of the method was performed by recovery studies. To the 50 % 
preanalysed formulation, a known quantity of Lafutidine and Domperidone raw 
material solutions were added at three different concentration levels. The absorbance 
of the solutions was measured and the percentage recovery was calculated. The 
percentage recovery was found to be in the range of 98.15-99.19% for Lafutidine and 
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99.71-100.01% for Domperidone. The average % RSD values of Lafutidine and 
Domperidone was found to be 0.5541 and 0.1653, respectively. The low % RSD 
value of drugs indicates that this method was accurate. The recovery data was shown 
in Table 19.  
5.3 RP – HPLC METHOD 
 An exertion has been made for a simple, rapid, accurate and precise method 
for the estimation of Lafutidine and  Domperidone  in  pure  form  and  in  
formulation  by  an  isocratic RP-HPLC method. 
 The  solutions  of  10 µg mL-1 of   Lafutidine and  Domperidone in mobile 
phase  [Methanol : 0.5% Ammonium Acetate buffer (85 : 15 % v/v)]  were  prepared  
and  the  solutions were scanned in the  range  of  200-400 nm. It  was  found  that the  
two  drugs  have  marked  absorbance  at  220 nm and can be effectively used for 
estimation of two drugs without interference. Therefore 220 nm was selected  as  
detection  wavelength  for the estimation  of  two  drugs  by RP-HPLC method with 
an isocratic  elution  technique  and  it  was  found  that  the two  drugs were stable for 
approximately one and half hour. 
 The  optimization  was  done  by  changing  the  composition  of  mobile phase  
ratio. The mobile phase consists of Methanol: Water (50:50 % v/v) was initially 
attempted and chromatograms were recorded and shown in Figure 14. Different ratios 
of mobile phase were attempted and the chromatograms recorded are shown in 15 and 
16.   Finally the mobile phase consists of Methanol : 0.5% Ammonium Acetate buffer 
(85:15% v/v). After calculating all system suitability test parameters, Methanol : 0.5% 
Ammonium Acetate buffer 85 : 15% v/v at a flow rate of 1 mL/min was selected and 
the optimized chromatograms individually and in combination are shown at       
Figure 17-19. The retention time of Lafutidine and Domperidone, were found to be 
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1.287 and 3.342, respectively.  The retention  time  between  two  drugs  indicate  that  
the  drugs  were separated with better resolution of 2.055. The system suitability 
parameters for the optimized chromatogram are shown in Table 20. 
 With the optimized chromatographic conditions, stock solutions of Lafutidine 
and Domperidone were prepared in mobile phase and prepared the in the 
concentration range of 35-65 µg mL-1 of Lafutidine, 105-195 µg mL-1 of  
Domperidone. 20 µL of each solution was injected and recorded the chromatograms 
at 220 nm. The chromatograms are shown in Figure 20-26. The calibration curve was 
plotted using concentration against peak area.  The procedure was repeated for three 
times.  The  Correlation  co-efficient  was  found  to  be  above  0.999  for  the  two  
drugs. The calibration graph of Lafutidine and Domperidone are shown in Figure 27 
and 28, respectively.  The optical characteristics of Lafutidine and Domperidone are 
shown in Table 21. 
 LAFAXID-D formulation containing 10 mg of Lafutidine and 30 mg of 
Domperidone was selected for analysis. The nominal concentration 150 µg mL-1 of 
Domperidone, which is also contains 50 µg mL-1 of Lafutidine  in  the mobile phase 
was prepared. 20 µL of each solution was injected and chromatograms were recorded. 
The percentage purity was found to be 100.42 ± 1.41 and 100.00 ± 0.8684 for 
Lafutidine and Domperidone, respectively. The precision of the method was 
confirmed by repeatability of formulation for three times at three levels i.e, 80 %,     
100 %, 120 % of the nominal concentration and the chromatograms are shown in       
Figure 29-37. The % RSD was found to be 0.7093 and 0.2673 for Lafutidine and 
Domperidone, respectively. It indicates that the method has good precision. The data 
is shown in Table 22. 
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 The accuracy of the method was performed by recovery studies. To the 
preanalyzed formulation, a known quantity of Lafutidine and Domperidone raw 
material solutions were added at different levels, injected the solutions. The 
chromatograms were recorded as shown in the Figure 38-40. The  percentage  
recovery  was  found  to  be  in  the  range  between  99.17 and 99.37 %  for  
Lafutidine and  99.35 and 100.81%  for Domperidone. The % RSD was found to be 
0.9488 and 0.9492 for Lafutidine and Domperidone, respectively. The low % RSD 
values for recovery indicated that the method was found to be accurate. The values 
are given in the Table 23.  
  All the above parameters with the ease of operation ensure that the 
projected methods could be applied for the routine analysis of Lafutidine and 
Domperidone in pure form and in tablet dosage forms. 
  
 
 
 
   Summary 
& 
  Conclusion
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6. SUMMARY AND CONCLUSION 
Simple, rapid, precise and accurate UV- Spectrophotometric method and            
RP-HPLC method were developed and validated for the estimation of Lafutidine and 
Domperidone in tablet dosage form.  
6.1. UV SPECTROSCOPIC METHODS 
From the solubility profile, methanol was chosen as a common solvent for the 
estimation of Lafutidine and Domperidone. The sample solutions of 10 µg mL-1 of 
Lafutidine and Domperidone in methanol prepared individually and the solutions 
were scanned in UV region in the wavelength range from 200-400 nm by using 
methanol as blank. The overlaid spectra of mixture of Lafutidine and Domperidone 
were recorded. From the spectra, 273 nm for Lafutidine and 287.5 nm for 
Domperidone was selected as wavelength to construct simultaneous equation.   
          The percentage label claim present in tablet formulation was found to be  
100.00 ± 1.874 and 100.36 ±1.841 for Lafutidine and Domperidone respectively. The 
percentage recovery was found to be in the range of 97.43-99.37% for Lafutidine and 
99.25-100.34% for Domperidone. 
 6.2   In area under the curve method, the wavelength ranges between 276 and 271 nm 
and 291 and 282 nm were selected for the estimation of Lafutidine and Domperidone 
respectively. The percentage label claim present in formulation was found to be  
99.49 ± 1.5994 and 100.36 ± 1.0945 for Lafutidine and Domperidone, respectively. 
The percentage recovery was found to be in the range of 98.15-99.19% for Lafutidine 
and 99.71-100.01% for Domperidone.  
6.3. RP-HPLC METHOD 
 In RP-HPLC method, mobile phase used is Methanol : 0.5% Ammonium 
Acetate  buffer  (85:15% V/V) with flow rate of 1 mL per min, the retention time of  
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Lafutidine and Domperidone were found to be 1.287 and 3.342, respectively  at      
220 nm. The retention time of Lafutidine is 1.287 which is less than the acceptable 
criteria and also the theoretical plate count is less than the acceptable criteria 
according to ICH guidelines. Because of the time and cost factor included the same.   
            The percentage purity was found to be 100.26 ± 0.7107 and 100.00 ± 0.4684 
for Lafutidine and Domperidone, respectively. The precision of the method was 
confirmed by repeatability of formulation for three times at three levels. The accuracy 
of the method was confirmed by recovery studies. The percentage recovery was found 
to be in the range of 99.17-99.37 % for Lafutidine and 99.35-100.81% for 
Domperidone. The % RSD was found to be 0.7093 and 0.2673 for Lafutidine and 
Domperidone, respectively.  The low % RSD values for recovery indicated that the 
method was accurate. 
 Simple, rapid and accurate UV Spectroscopic (Simultaneous Equation method 
and Area under curve method) and an isocratic RP-HPLC method showed excellent 
Sensitivity, Reproducibility, Accuracy, and Repeatability, which is evidenced by low 
%RSD. The results obtained in recovery studies were indicating that there is no 
interference from the excipients used in the formulation. By comparing two methods, 
UV Spectroscopic methods were found to be economic when compared to RP-HPLC. 
Hence it is suggested that the proposed UV Spectroscopic and an isocratic RP-HPLC 
methods can be effectively applied for the routine analysis of Lafutidine and 
Domperidone in bulk and in tablet formulation and the obtained results will be 
presented elsewhere.      
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FIGURE 1 
                        IR SPECTRUM OF LAFUTIDINE 
 
    
 
 
  
 
FIGURE 2 
IR SPECTRUM OF DOMPERIDONE 
 
 
 
 
  
 
FIGURE 3 
UV- SPECTRUM OF LAFUTIDINE IN METHANOL 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE-4 
UV SPECTRUM OF DOMPERIDONE IN METHANOL 
 
 
 
 
 
 
 
 
 
  
 
FIGURE 5 
OVERLAIN SPECTRUM OF LAFUTIDINE AND DOMPERIDONE IN 
METHANOL   
                    
  
 
 
 
 
 
 
 
 
 
 
  
 
FIGURE 6 
          CALIBRATION CURVE OF LAFUTIDINE IN METHANOL AT 273 nm  
          SIMULTANEOUS EQUATION METHOD 
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FIGURE 7 
       CALIBRATION CURVE OF LAFUTIDINE IN METHANOL AT 287.5 nm  
    SIMULTANEOUS EQUATION METHOD 
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 FIGURE 8 
    CALIBRATION CURVE OF DOMPERIDONE IN METHANOL AT 273 nm  
SIMULTANEOUS EQUATION METHOD 
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FIGURE 9 
CALIBRATION CURVE OF DOMPERIDONE IN METHANOL AT 287.5 nm  
SIMULTANEOUS EQUATION METHOD 
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                                                      FIGURE 10               
   CALIBRATION CURVE OF LAFUTIDINE IN METHANOL AT 276-271 nm  
AREA UNDER CURVE METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.1972
0.3924
0.5781
0.7856
0.9983
0
0.2
0.4
0.6
0.8
1
1.2
0 5 10 15 20 25
AB
SO
R
B
AN
CE
CONCENTRATION[MCG/ML]
CALIBRATION CURVE 
  
 
FIGURE 11 
CALIBRATION CURVE OF LAFUTIDINE IN METHANOL AT 291-282 nm  
AREA UNDER CURVE METHOD 
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     FIGURE 12 
CALIBRATION CURVE OF DOMPERIDONE IN METHANOL AT 
            276-271 nm AREA UNDER CURVE METHOD 
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FIGURE 13      
CALIBRATION CURVE OF DOMPERIDONE IN METHANOL AT 
                     291-282 nm   AREA UNDER CURVE METHOD 
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FIGURE 14 
INITIAL SEPARATION CONDITIONS IN METHANOL: WATER  
                                                  50:50%V/V                               
 
  
 
FIGURE 15 
EFFECT OF RATIO OF MOBILE PHASE 
METHANOL: 0.5% AMMONIUM ACETATE BUFFER (50:50 % V/V) 
 
 
  
 
FIGURE 16 
EFFECT OF RATIO OF MOBILE PHASE 
METHANOL: 0.5% AMMONIUM ACETATE BUFFER (60:40 % V/V)  
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FIGURE 17 
F LAFUTIDINE IN MOBILE PHASE
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FIGURE 18 
F DOMPERIDONE IN MOBILE PHASE
 
 
 
 
 
 
  
 
FIGURE 19 
OPTIMIZED CHROMATOGRAM OF LAFUTIDINE AND DOMPERIDONE  
IN MOBILE PHASE                                        
 
 
 
 
                                                        
  
                                                        
LINEARITY CHROMATOGRAM O
 
 
 FIGURE 20 
F LAFUTIDINE AND DOMPERIDONE 
(35, 105 µg/ mL)                                                                             
 
 
 
 
 
  
 LINEARITY CHROMATOGRAM OF LAFUTIDINE AND DOMPERIDONE 
 
FIGURE 21 
(40, 120 µg/ mL) 
 
 
 
 
 
  
                                                          
LINEARITY CHROMATOGRAM O
 
 
FIGURE 22 
F LAFUTIDINE AND DOMPERIDONE 
(45, 135 µg/ mL) 
 
 
 
 
  
 LINEARITY CHROMATOGRAM OF LAFUTIDINE AND DOMPERIDONE 
 
FIGURE 23 
(50, 150 µg/ mL) 
 
 
 
 
 
  
LINEARITY CHROMATOGRAM OF LAFUTIDINE AND DOMPERIDONE 
                                                 
 
FIGURE 24 
(55, 165 µg/ mL) 
  
   
 
   
      
 
  
  LINEARITY CHROMATOGRAM OF LAFUTIDINE AND DOMPERIDONE 
 
FIGURE 25 
(60, 180 µg/ mL) 
  
  LINEARITY CHROMATOGRAM OF LAFUTIDINE AND DOMPERIDONE 
 
FIGURE 26 
(65, 195 µg/ mL) 
 
 
 
 
 
  
 
FIGURE 27 
CALIBRATION CURVE OF LAFUTIDINE RP-HPLC 
 
 
 
 
 
 
 
 
 
 
0
665433
759021
849833
946271
1037244
1134119
1227637
0
200000
400000
600000
800000
1000000
1200000
1400000
0 10 20 30 40 50 60 70
AR
EA
CONCENTRATION[MCG/ML]
CALIBRATION CURVE 
  
 
FIGURE 28 
CALIBRATION CURVE OF DOMPERIDONE RP-HPLC 
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FIGURE 29 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION LAFAXID-D 
REPEATABILITY – 1 
 
 
 
                                                             
       
 
 
  
 
      FIGURE 30 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION LAFAXID- D 
REPEATABILITY – 2 
 
 
       
 
     
 
 
  
 
     FIGURE 31 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION LAFAXID- D 
REPEATABILITY – 3 
 
 
 
 
  
  
 
FIGURE 32 
CHROMATOGRAM FOR ANALYSIS OF FORMULATION LAFAXID- D 
REPEATABILITY – 4 
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FIGURE 33 
REPEATABILITY – 5 
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FIGURE 34 
        REPEATABILITY – 6 
 
 
   
 
 
- D 
 
  
CHROMATOGRAM FOR ANALYSIS OF FORMULATION 
 
 
FIGURE 35 
    REPEATABILITY – 7 
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 FIGURE 36 
REPEATABILITY – 8 
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  FIGURE 37 
REPEATABILITY – 9 
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                                                          TABLE 1 
SOLUBILITY PROFILE OF LAFUTIDINE AND DOMPERIDONE   IN 
POLAR AND NON-POLAR SOLVENTS 
 
 
 
 
S.No. 
SOLVENTS LAFUTIDINE 
10 mg in mL of solvent 
DOMPERIDONE 
10 mg in mL of solvent 
1 Acetone Freely soluble (60 µL) Soluble(200  µL) 
2 Acetonitrile Sparingly soluble(400  µL) Insoluble(100 mL) 
3 Benzene Sparingly soluble(500  µL)  Insoluble(100 mL) 
4 Butanol Freely soluble(40  µL) Slightly soluble(5 mL) 
5 Carbon tetra chloride Slightly soluble(1 mL)  Insoluble(100 mL) 
6 Chloroform Very soluble(10  µL)           Insoluble(100 mL) 
7 Dichloromethane Freely soluble(20  µL) Insoluble(100 mL) 
8 Distilled water  Insoluble(100 mL)       Insoluble(100 mL) 
9 DMF Freely soluble(30  µL)  Soluble(200  µL) 
10 Ethyl acetate Freely soluble(100  µL) Insoluble(100 mL) 
   11 Hydrochloric acid 
(0.1M) 
Sparingly soluble(400  µL)      Insoluble(100 mL) 
12 Methanol Freely soluble(30  µL) Slightly Soluble(5 mL) 
13 Sodium Hydroxide 
(0.1M) 
 Insoluble(100 mL) Slightly soluble(6 mL) 
  
                                                     TABLE 2 
       OPTICAL CHARACTERISTICS OF LAFUTIDINE  
           SIMULTANEOUS EQUATION METHOD 
 
 
 
 
                       
 
Parameters              At 273 nm           At 287.5 nm 
Beers law limit (µg mL-1) 4 – 20 4 – 20 
Sandell’s sensitivity  
(µg/cm2/0.001 A.U) 0.096932 0.436137 
Molar absorptivity 4428.4222 982.4955 
Correlation coefficient (r) 0.99978 0.99966 
Régression equation 
 (y = mx+c) y = 0.010316x - 0.00055 y = 0.002293x - 0.00016 
Slope (m) 0.010316 0.002293 
Intercept (c) - 0.00055 -0.00016 
LOD (µg mL-1) 0.1623455 1.538328 
LOQ (µg mL-1) 0.491956 4.661601 
Standard Error 0.001429 0.0005 
  
                      TABLE 3 
          OPTICAL CHARACTERISTICS OF DOMPERIDONE  
SIMULTANEOUS EQUATION METHOD 
 
 
 
 
PARAMETERS AT 273 nm AT 287.5 nm 
Beers law limit (µg mL-1) 12 - 60 12 – 60 
Sandell’s sensitivity 
(µg/cm2/0.001 A.U) 0.065785 0.032894 
Molar absorptivity 6544.005 12739.982 
Correlation coefficient (r) 0.9997 0.99958 
Régression equation (y = mx+c) 
y = 0.015201x 
+0.001638 
y = 0.0304x - 0.00488  
Slope (m) 0.015201 0.0304 
Intercept (c) 0.001638 -0.00488 
LOD (µg mL-1) 0.0202818 0.268180 
LOQ (µg mL-1) 0.0614602 0.8126696 
Standard Error 0.009294 0.022013 
  
TABLE 4 
QUANTIFICATION OF FORMULATION (LAFAXID-D)       
SIMULTANEOUS EQUATION METHOD 
 
Drug 
Sample 
No. 
Labeled 
amount* 
(mg/tab) 
Amount 
found* 
(mg/tab) 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
 
LAF 
 
 
1 
2 
3 
4 
5 
 
10 
10 
10 
10 
10 
 
9.849 
9.948 
9.738 
9.745 
9.988 
 
98.49 
99.48 
97.38 
97.45 
99.88 
 
 
 
98.536 
 
 
 
 
1.14185 
 
 
 
 
1.1588 
 
 
 
 
0.04567 
 
 
 
 
 
DOM 
 
 
1 
2 
3 
4 
5 
 
30 
30 
30 
30 
30 
 
29.98 
29.86 
29.79 
30.108 
30.09 
 
99.93 
99.53 
99.3 
100.36 
100.3 
 
 
 
99.88 
 
 
 
 
0.4658 
 
 
 
0.4664 
 
 
 
 
 
0.01863 
 
 
 
* Mean of five observations 
 
 
 
 
  
                                                                       TABLE 5    
INTRADAY AND INTERDAY ANALYSIS OF FORMULATION 
(LAFAXID-D) SIMULTANEOUS EQUATION METHOD 
 
 
* Mean of five observations 
Drug 
Sample 
No. 
Labeled 
amount 
(mg/ tab) 
Percentage 
obtained*
 
S.D. % R.S.D. Standard error 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
LAF 
1 
2 
3 
10 
10 
10 
98.04 
98.09 
98.14 
98.84 
99.67 
98.04 
0.0500 0.8150 0.0510 0.8245 0.0056 0.0906 
Mean 98.09 98.815  
 
 
DOM 
 
1 
2 
3 
30 
30 
30 
99.18 
98.18 
98.06 
99.87 
98.94 
98.64 
0.6149 0.6413 
 
0.6245 
 
0.6468 0.0683 0.0713 
Mean 98.47 99.15  
  
 
TABLE 6 
                                   RUGGEDNESS STUDY (LAFAXID-D)  
                                SIMULTANEOUS EQUATION METHOD 
       
Drug Condition 
Sample 
No. 
Amount 
found 
(mg/ tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
Analyst-1 
 
1 
2 
3 
4 
5 
 
9.899 
9.969 
9.754 
9.99 
9.875 
 
98.99 
99.69 
97.54 
99.9 
98.75 
 
 
 
98.974 
 
 
 
0.9323 
 
 
 
0.9419 
 
 
 
0.03729 
 
 
 
DOM 
 
 
 
Analyst-1 
 
 
 
1 
2 
3 
4 
5 
 
29.98 
29.88 
29.92 
30.06 
30.08 
 
99.93 
99.6 
99.73 
100.2 
100.26 
 
 
 
99.944 
 
 
 
 
0.2871 
 
 
 
0.2872 
 
 
 
 
0.01148 
 
 
 
* Mean of five observations 
  
  
TABLE 7 
RUGGEDNESS STUDY (LAFAXID-D)  
 SIMULTANEOUS EQUATION METHOD  
 
Drug Condition 
Sample 
No. 
Amount 
found 
(mg/ 
tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
Analyst-2 
 
 
 
1 
2 
3 
4 
5 
 
9.919 
9.982 
9.99 
9.96 
9.93 
 
99.19 
99.82 
99.9 
      99.6 
99.3 
 
 
 
99.562 
 
 
 
0.3119 
 
 
 
 
0.3133 
 
 
 
 
0.0124 
 
 
 
 
DOM 
 
 
 
Analyst-2 
 
1 
2 
3 
4 
5 
 
30.06 
30.01 
29.88 
29.89 
29.88 
 
100.2 
100.03 
99.6 
99.63 
99.6 
 
 
 
99.812 
 
 
 
0.2833 
 
 
 
0.2838 
 
 
 
 
 
 
0.01133 
 
 
 
 
* Mean of five observations 
  
  
TABLE 8 
RUGGEDNESS STUDY (LAFAXID-D) 
 SIMULTANEOUS EQUATION METHOD 
 
Drug Condition 
Sam
ple 
 No. 
Amount 
found 
(mg/ tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
Instrument-1 
 
1 
2 
3 
4 
5 
 
9.8694 
10.05 
9.832 
9.87 
10.00 
 
98.69 
100.5 
98.32 
98.70 
100.00 
 
 
 
99.242 
 
 
 
 
0.9494 
 
 
 
 
0.9566 
 
 
 
 
0.0379 
 
 
 
 
DOM 
 
 
 
 
 
Instrument-1 
 
 
1 
2 
3 
4 
5 
 
30.03 
30.05 
29.86 
30.1 
29.79 
 
100.1 
100.16 
99.53 
100.33 
99.3 
 
 
 
99.88 
 
 
 
 
 
0.4438 
 
 
 
0.4443 
 
 
 
 
 
 
0.0177 
 
 
 
 
* Mean of five observations 
 
 
  
TABLE 9 
RUGGEDNESS STUDY (LAFAXID-D) 
 SIMULTANEOUS EQUATION METHOD 
 
Drug Condition 
Sample 
No. 
Amount 
found 
(mg/ tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
 
Instrument-2 
 
 
1 
2 
3 
4 
5 
 
9.929 
9.949 
9.934 
9.754 
9.858 
 
99.29 
99.49 
99.34 
97.54 
98.58 
 
 
 
98.848 
 
 
 
 
0.8112 
 
 
 
 
0.8206 
 
 
 
 
0.0324 
 
 
 
 
DOM 
 
 
 
Instrument-2 
 
 
1 
2 
3 
4 
5 
 
30.02 
30.10 
29.89 
29.86 
29.98 
 
100.06 
100.33 
99.63 
99.53 
99.93 
 
 
 
99.896 
 
 
 
0.3244 
 
 
 
0.3248 
 
 
 
 
 
 
0.0129 
 
 
 
 
* Mean of five observations 
 
 
  
 
TABLE 10 
RECOVERY ANALYSIS OF FORMULATION  
(LAFAXID-D) SIMULTANEOUS ESTIMATION METHOD 
  
 
* Mean of Three Observations 
 
 
 
 
Drug S. No 
Amount 
present* 
(µg/ ml) 
Amount 
added* 
(µg/ ml) 
Amount 
estimated* 
(µg/ ml) 
Amount 
recovered* 
(µg/ ml) 
% 
Recovery* 
Mean 
% 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
1 
 
2 
 
3 
 
6.0155 
 
6.0155 
 
6.0155 
 
9.6095 
 
12.046 
 
14.406 
 
15.4880 
 
17.7495 
 
20.1382 
 
9.4825 
 
11.8440 
 
14.136 
 
98.67 
 
98.32 
 
98.125 
 
 
 
98.37 
 
 
 
 
0.2761 
 
 
 
 
0.2807 
 
 
 
 
 
0.0306 
 
 
 
 
 
DOM 
 
 
 
1 
 
2 
 
3 
 
 
18.0659 
 
18.0659 
 
18.0659 
 
28.8315 
 
36.0233 
 
43.2745 
 
46.7167 
 
53.7822 
 
61.1326 
 
28.7353 
 
35.7818 
 
43.1369 
 
99.66 
 
99.32 
 
99.68 
 
 
 
99.55 
 
 
 
 
 
0.2023 
 
 
 
 
 
0.2032 
 
 
 
 
0.0224 
 
 
  
TABLE 11        
OPTICAL CHARACTERISTICS OF LAFUTIDINE   
AREA UNDER CURVE METHOD 
 
 
 
      
Parameters              At 276-271 nm           At 291-282 nm 
Beers law limit (µg mL-1) 4 – 20 4 – 20 
Sandell’s sensitivity  
(µg/cm2/0.001 A.U) 0.020165 0.033825 
Molar absorptivity 21229.38 12563.14 
Correlation coefficient (r) 0.99976 0.99955 
Régression equation  
(y = mx+c) y = 0.049589x - 0.00395 y = 0.029564x - 0.00452 
Slope (m) 0.049589 0.029564 
Intercept (c) - 0.00395 -0.00452 
LOD (µg mL-1) 0.076977 0.128102 
LOQ (µg mL-1) 0.23326 0.38818 
Standard Error 0.00891 0.00742 
  
                                                          TABLE 12 
       OPTICAL CHARACTERISTICS OF DOMPERIDONE   
AREA UNDER CURVE METHOD 
 
 
 
                                                 
 
PARAMETERS AT 276-271 nm AT 291-282 nm 
Beers law limit (µg mL-1) 12 – 60 12 – 60 
Sandell’s sensitivity   
(µg/cm2/0.001 A.U) 0.01257 0.003938 
Molar absorptivity 34255.231 109225.025 
Correlation coefficient (r) 0.99968 0.9997 
Régression equation (y = mx+c) y = 0.0794x +0.008967 y = 0.25485x +0.01902  
Slope (m) 0.07943 0.25485 
Intercept (c) 0.008967 0.01902 
LOD (µg mL-1) 0.012033 0.107255 
LOQ (µg mL-1) 0.036463 0.325016 
Standard Error 0.05071 0.16258 
  
        TABLE 13 
QUANTIFICATION OF FORMULATION (LAFAXID-D)   
AREA UNDER CURVE METHOD 
 
 
Drug 
Sample 
No. 
Labeled 
amount 
(mg/ tab) 
Amount 
found 
(mg/ tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
 
LAF 
 
1 
2 
3 
4 
5 
 
10 
10 
10 
10 
10 
 
9.932 
9.832 
9.762 
9.858 
9.949 
 
99.32 
98.32 
97.62 
98.58 
99.49 
 
 
 
98.606 
 
 
 
0.8699 
 
 
 
0.8822 
 
 
 
0.0348 
 
 
 
 
DOM 
 
 
1 
2 
3 
4 
5 
 
30 
30 
30 
30 
30 
 
30.01 
30.02 
29.79 
29.89 
30.108 
 
100.03 
100.06 
99.3 
99.63 
100.36 
 
 
 
99.876 
 
 
 
 
0.4135 
 
 
 
0.41407 
 
 
 
 
0.0165 
 
 
* Mean of five observations 
 
 
 
 
  
TABLE 14 
INTRADAY AND INTERDAY ANALYSIS OF FORMULATION 
(LAFAXID-D) AREA UNDER CURVE METHOD  
 
Drug 
Sample 
No. 
Labeled 
amount 
(mg/ 
tab) 
Percentage 
obtained*
 
S.D. % R.S.D. Standard error 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
LAF 
1 
2 
3 
10 
10 
10 
99.32 
100.03 
98.32 
98.12 
99.48 
98.49 
0.8590 0.7031 0.8658 0.7124 0.0954 0.0781 
Mean 99.22 98.696  
 
 
DOM 
 
1 
2 
3 
30 
30 
30 
99.56 
100.05 
99.79 
99.6 
99.41 
100.64 
0.2451 0.6621 
 
0.2456 
 
0.6629 0.0272 0.0735 
Mean 99.8 99.88  
* Mean of five observations 
  
 
TABLE 15 
RUGGEDNESS STUDY (LAFAXID- D) AREA UNDER CURVE METHOD 
 
Drug Condition 
Sample 
No. 
Amount 
found 
(mg/ tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
 
Analyst-1 
 
 
 
 
1 
2 
3 
4 
5 
 
 
9.932 
9.896 
9.958 
9.832 
9.891 
 
 
99.32 
98.96 
99.58 
98.32 
98.91 
 
 
 
 
99.018 
 
 
 
 
0.4767 
 
 
 
 
0.4815 
 
 
 
 
0.01907 
 
 
 
 
DOM 
 
 
 
 
 
Analyst-1 
 
 
 
 
1 
2 
3 
4 
5 
 
 
30.06 
29.98 
29.89 
30.108 
29.92 
 
 
100.2 
99.95 
99.63 
100.36 
99.74 
 
 
 
 
 99.976 
 
 
 
 
 
 
0.3056 
 
 
 
0.3057 
 
 
 
 
 
 
0.01222 
 
 
 
 
* Mean of five observations 
  
  
TABLE 16 
RUGGEDNESS STUDY (LAFAXID-D) AREA UNDER CURVE METHOD 
Drug Condition 
Sample 
No. 
Amount 
found 
(mg/ tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
 
Analyst-2 
 
 
 
 
1 
2 
3 
4 
5 
 
 
9.732 
9.865 
9.768 
9.89 
9.923 
 
 
97.32 
98.65 
97.68 
      98.9 
99.23 
 
 
 
 
98.356 
 
 
 
 
0.818 
 
 
 
 
0.8316 
 
 
 
 
0.0327 
 
 
 
 
DOM 
 
 
 
 
 
Analyst-2 
 
 
 
 
1 
2 
3 
4 
5 
 
 
29.983 
29.862 
29.732 
29.2 
30.02 
 
 
99.94 
99.54 
99.1 
97.34 
100.06 
 
 
 
 
99.196 
 
 
 
 
 
 
1.1036 
 
 
 
1.1126 
 
 
 
 
 
 
0.0441 
 
 
 
 
* Mean of five observations 
  
TABLE 17 
RUGGEDNESS STUDY (LAFAXID-D) AREA UNDER CURVE METHOD 
 
 
Drug Condition 
Sample 
 No. 
Amount 
found 
(mg/ 
tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
Instrument-1 
 
 
 
1 
2 
3 
4 
5 
 
9.89 
9.966 
9.754 
9.99 
9.875 
 
99.89 
99.66 
97.54 
99.9 
98.75 
 
 
 
99.148 
 
 
 
1.015 
 
 
 
1.023 
 
 
 
0.0406 
 
 
 
DOM 
 
 
 
Instrument-1 
 
 
1 
2 
3 
4 
5 
 
30.03 
30.05 
29.86 
29.94 
29.79 
 
 
100.1 
100.16 
99.53 
99.8 
99.3 
 
 
 
99.77 
 
 
 
 
 
 
0.3674 
 
 
 
0.3682 
 
 
 
 
 
 
0.0146 
 
 
 
 
* Mean of five observations 
  
  
TABLE 18 
RUGGEDNESS STUDY (LAFAXID-D) AREA UNDER CURVE METHOD 
Drug Condition 
Sample 
No. 
Amount 
found 
(mg/ tab)* 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
 
 
Instrument-
2 
 
 
1 
2 
3 
4 
5 
 
9.826 
9.93 
9.892 
9.902 
9.804 
 
98.26 
99.3 
98.92 
99.02 
98.04 
 
 
 
98.708 
 
 
 
 
0.5337 
 
 
 
 
0.5407 
 
 
 
 
0.0213 
 
 
 
 
DOM 
 
 
 
Instrument-
2 
 
1 
2 
3 
4 
5 
 
29.932 
29.621 
30.03 
29.727 
30.126 
 
99.77 
98.73 
100.1 
99.09 
100.42 
 
 
 
99.622 
 
 
 
 
0.701 
 
 
 
0.7037 
 
 
 
 
 
 
0.028 
 
 
 
 
* Mean of five observations 
 
 
                                                                  
  
                                                            TABLE 19 
RECOVERY ANALYSIS OF  
(LAFAXID-D) AREA UNDER CURVE METHOD  
 
 
* Mean of Three Observations 
 
 
 
 
 
Drug S. No 
Amout 
present* 
(µg/ ml) 
 Amont 
added* 
(µg/ml) 
Amount 
estimated* 
(µg/ ml) 
Amount  
recovered* 
(µg/ ml) 
% 
Recovery* 
Mean 
% 
S.D. 
% 
R.S.D. 
S.E. 
 
 
 
LAF 
 
1 
 
2 
 
3 
 
6.0155 
 
6.0155 
 
6.0155 
 
9.6095 
 
12.046 
 
14.406 
 
15.548 
 
17.8395 
 
20.1882 
 
9.5325 
 
11.824 
 
14.1727 
 
99.19 
 
98.15 
 
98.38 
 
 
 
98.573 
 
 
 
 
0.5462 
 
 
 
 
0.5541 
 
 
 
 
 
0.0606 
 
 
 
 
 
DOM 
 
 
 
1 
 
2 
 
3 
 
 
18.0659 
 
18.0659 
 
18.0659 
 
28.8315 
 
36.0233 
 
43.2745 
 
46.9024 
 
53.9876 
 
61.3342 
 
28.8365 
 
35.9217 
 
43.2683 
 
100.01 
 
99.71 
 
99.98 
 
 
 
99.9 
 
 
 
 
 
0.1652 
 
 
 
 
 
0.1653 
 
 
 
 
0.0407 
 
 
  
TABLE 20 
SYSTEM SUITABILITY PARAMETERS FOR THE OPTIMIZED  
CHROMATOGRAM RP-HPLC 
PARAMETERS LAFUTIDINE                           DOMPERIDONE 
Retention time 1.287 3.342 
Tailing factor 0.5 1 
Asymmetrical factor 1.30 1.69 
Theoretical plates 1084 1513 
Capacity factor 0.832 3.77 
Resolution Between LAF and DOM 7.26 
 
 
  
  
                                                        TABLE 21 
OPTICAL CHARACTERISTICS OF LAFUTIDINE AND 
DOMPERIDONE RP-HPLC 
PARAMETERS LAFUTIDINE                   DOMPERIDONE 
λmax (nm) 220 220 
Beers law limit (µg/ml) 35-65 105-195 
Correlation coefficient (r) 0.9999 0.9999 
Regression equation                     
(y = mx + c) 
y = 18744.4214x + 
8430.0714 
y = 13596.2357x – 
73555.7857 
Slope (m) 18744.4214 13596.2357 
Intercept (c) 8430.0714 -73555.7857 
LOD (µg/ ml) 0.011058 0.015419 
LOQ (µg/ ml) 0.0335102 0.046726 
Standard Error          2147.368 14279.602 
  
 
                                                           TABLE 22 
QUANTIFICATION OF TABLET FORMULATION (LAFAXID- D) RP – HPLC 
 
 
Drug 
Sample 
No. 
Labeled 
amount 
(mg/ 
tab) 
Amount 
found 
(mg/ 
tab) 
 
Percentage 
Obtained* 
Average 
(%) 
S.D. 
% 
R.S.D. 
S.E. 
LAF 
Low level 
(80 %)  
Middlelevel 
(100 % ) 
High level 
(120 %) 
       
       10 
       10 
       10 
       
      10.04 
        9.96 
        9.9 
 
100.42 
99.62 
99.01 
 
 
99.68 
 
 
0.7071 
 
0.7093 
 
0.0785 
DOM 
 
Low level 
(80 %)  
Middlelevel 
(100 % ) 
High level 
(120 %) 
        30 
        30          
        30 
29.81 
29.74 
29.9 
99.37 
99.14 
99.67 
99.39 0.2675 0.2673 0.0295 
         
* Mean of three observations 
 
 
 
 
 
 
 
 
  
 
                                                                   TABLE 23 
          RECOVERY ANALYSIS OF FORMULATION (LAFAXID- D) RP-HPLC  
 
* Mean of Three Observations 
 
 
 
Drug S. 
No 
Amount 
present 
(µg/ ml) 
Amount 
added* 
(µg/ ml) 
Amount 
found* 
(µg/ ml) 
Amount  
recovered* 
(µg/ ml) 
% 
Recovery* 
Mean  
% S.D. 
% 
R.S.D. S.E. 
LAF 
 
 
1 
2 
3 
 
 
50 
50 
50 
 
 
    
     5 
    10 
    15 
 
 
54.987 
60.103 
64.878 
 
 
4.987 
10.103 
14.878 
 
 
99.74 
101.03 
99.18 
 
 
 
99.98 
 
 
 
 
0.9487 
 
 
 
 
0.9488 
 
 
 
 
0.1054 
 
 
 
DOM 
 
1 
2 
3 
 
150 
150 
150 
 
15 
30 
40 
 
164.756 
179.912 
190.078 
 
14.756 
29.912 
40.078 
 
98.37 
99.70 
100.195 
 
99.42 
 
 
0.9438 
 
 
0.9492 
 
 
0.1048 
 
  
 
 
 
  Bibliography 
 
 
 
 
 
 
 
 
 
 68 
 
                                                                BIBILOGRPHY 
1. Ahsanul Haque Md., Mohammad shahriar., Most. Nazma Parvin and Ashraful 
Islam S.M. Validated RP-HPLC method for estimation of Ranitidine HCl, 
Domperidone and Naproxen in solid dosage form, Asian Journal Pharmaceutical 
Analysis, 2011, 1(3),   59-63. 
2. Anjaneyulu Y., Chandra  sekhar  K.  and Valli  Manickam.  A  Text  Book  of 
 
               Analytical Chemistry. Pharmamed press, Hyderabad, 2006, 1-4. 
 
3. Anonymous www.ajrconline.org. 
4. Anonymous www.asianpharmaonline.org. 
5. Anonymous, ijpqa.com. 
6. Anonymous, The Indian Pharmacopoeia. The Controller of Publication, New Delhi, 
2007, (II), 1051- 1053. 
7. Anonymous, The Merck Index. 14th edn., Merck Research Laboratories Division of 
Merck & Co. Inc, USA, 2006, 3417,5347. 
8. Anonymous, www.drugbank.com 
9. Anonymous, www.en.wikipedia.org/wiki/Lafutidine 
10. Anonymous, www.Sphinsai.com 
11. Anonymous,www.pelagiaresearchlibrary.com. 
12. Anonymous.www.askaboutvalidation.com/forum/showthread.php?t=1175. 
13. Anonymous.www.upchurch.com.cn/images/TechInfo/hplcThumb.gif. 
14. Ashutoshkar. Pharmaceutical Drug Analysis. 2nd edition, New Age International (P) 
Limited, New Delhi, 2005, 456 – 462. 
15. Beckett A.H. and Stenlake. J.B. Practical Pharmaceutical Chemistry. 4th edn., CBS 
Publishers and Distributors, New Delhi, 2007, (II), 259, 260, 278-290, 293-297. 
 69 
 
16. Code Q2A, Text on Validation of Analytical Procedures. ICH Harmonized 
Tripartite Guidelines, Geneva, Switzerland, 27th October, 1994, 1-5. 
17. Code Q2B, Validation of Analytical Procedures. Methodology. ICH Harmonized 
Tripartite Guidelines, Geneva, Switzerland, 6th November, 1996, 1-8. 
18. Day R.A. and Underwood AL. Quantitative Analysis. 6th edition, Prentice- Hall of 
India Pvt. Ltd., 2006, 2. 
19. Ding Hong-liang., Zhang Gen- vuan. Reported Determination of Lafutidine by 
HPLC, North West Pharmaceutical Journal, 2009, I. 
20. Gurdeep R. Chatwal and Sham K. Anand. Instrumental Methods of Chemical 
Analysis. Reprint., Himalayan Publishing House, Mumbai, 2007, 1.2, 1.3, 2.149, 
2.150, 2.108,2.109, 2.112, 2.113, 2.161, 2.167, 2.168, 2.169, 2.567. 
21. Karla Kapil., naik S., Jarmal Garima. and Mishra N. Spectrophotometric method for 
Simultaneous estimation of Paracetamol and Domperidone in tablet dosage 
formulation, Asian Journal of Research Chemistry, 2009, 2(2). 
22. Koujirou Yamamoto., Mami Hagingo., Hajim Kotaki., Tatsuji Iga. Reported 
Quantitative determination of Domperidone in plasma by HPLC with fluorescence 
detection, Journal of Chromatography Biomedical sciences and Application, 1988, 
720(1), 251-255. 
23. Kouzuro Ikawa., Tomohiko Shimatani., Seiichi Hayoto., Norifumi Murikawa., 
Susuma Tazuma. Pharmacokinetic and pharmacodynamic properties of Lafutidine 
after post prandial oral administration in healthy subjects: Comparison with 
famotidine, Biological and Pharmaceutical Bulletin, 2007, 30(5), 1003.  
24. Lakshmana Prabu S., Shirwaikar A., Annie Shirwaikar., Dinesh kumar C., Joseph 
A. and  Kumar R. Simultaneous estimation of Esomeprazole and Domperidone by 
 70 
 
UV spectrophotometric method, Indian Journal of Pharmaceutical Sciences, 2008, 
70(1), 124-128.  
25. Lakshmi sivasubramanian., Anil kumar v. Simultaneous estimation of Omeprazole 
and Domperidone from tablets by HPLC, Indian Journal of Pharmaceutical 
Sciences, (2007), 69(5), 674-676.            
26. Lili Wu., Zunjian Zhang., Yuan Tian. Reported Determination of Lafutidine in 
human plasma by HPLC – electro spray ionization mass spectrometry : Application 
to bio-equivalence study,  Journal of Mass Spectrometry, 2009, 40(12), 1637-1643. 
27. Mendham J., Denny R.C., Barnes J.D. and Thomas M.J.K. Vogel’s Text Book of 
Quantitative Chemical Analysis. 6th edition, Pearson education, New Delhi, 2002,  
133-140. 
28. Namitha P., Vasantharaju.,  Archana Gunda S.G., Sudheer Moorkoth., Karthik A. 
and Bhat K.M. Reported Quantification of Domperidone, Paracetamol, 
Esomeprazole and Lansoprazole in pharmaceutical dosage form by RP-HPLC, 
Indian Drugs, 2005, 42(4), 158-161. 
29. Onodera S., Shibata M., Tanaka M., Inaba N., Ariya Y., Aoyoma M., Lec B., 
Yamura T. Gastroprotective mechanism of Lafutidine, a novel anti-ulcer drug with 
Histamine H2- Receptor antagonist activity, Arzneimittelforchung, 1999,  49(6), 
512-526. 
30. Patel A.H., Patel J.K., Rajput G.C., Rajgor N.B. Development and validation of 
Derivative spectrophotometric method for simultaneous estimation of Domperidone 
and Rabelprazole Sodium in bulk and dosage form, International journal on 
Pharmaceutical and Biological Research, 2010, 1(1), 1-5. 
 71 
 
31. Priti D. Trivedi and Dilip G. Maheswari. Estimation of Esomeprazole and 
Domperidone by Absorption Ratio method in Pharmaceutical dosage form. 
International Journal of Chem Tech Research, 2010, 2(3), 1598-1605.   
32. Rakesh Kumar Singh., Rama Krishna S. and Pragya Gupta RP-HPLC method 
development and validation for simultaneous estimation of Ranitidine HCl and 
Domperidone in combined tablet dosage form, International Journal of 
Pharmaceutical Sciences and Research, 2010, 1(8), 77-87. 
33. Ramesh sawanth., Lokesh Bhangale., Rupali Joshi. and Prashanth Lanke. Reported 
validated spectrophotometric methods for simultaneous estimation of Paracetamol, 
Domperidone and Tramadol HCl in pure and tablet dosage form, Journal of 
Chemical Metrology, 2010, 4(1), 21-27.   
34.  Ravikumar P., Bhanu prakash P., Murali Krishna M., Santha Yadav M. and Asha 
Deepthi C. Simultaneous estimation of Domperidone and Pantaprozole in solid 
dosage form by U.v spectrophotometry, E-Journal of Chemistry, 2006, 3(12), 142-
145. 
35. Sethi P.D. Quantitative Analysis of drug in Pharmaceutical formulations. 3rd 
edition, CBS Publisher and Distributors, New Delhi, 2003, 4. 
36. Shangguan Ying-Ying., Shi Ting., He Xian-Chen. Determination of related 
substances in Lafutidine by RP-HPLC, Northwest Pharmaceutical Journal, 2005, 
4(16). 
37. Sharma B. K. Instrumental Methods of Chemical Analysis. 25th edition, Goel 
Publishing House, Meerut, India, 2006, 68 – 192, c - 315.   
38. Sharma Y.R. Elementary Organic Spectroscopy. 4th Revised and enlarged edn.,          
Chand S. and Company Ltd., New Dehli, 2007, 5-11. 
 72 
 
39. Shen Qian., Li Huan-ming., Wang yu-qin. Reported Determination of Lafutidine 
concentration in human blood serum by HPLC, Chinese Pharmaceutical Journal, 
2007, 42(17), 1343-1344. 
40. Shozan Mondal Md., Ahsanul Haque Md., Mohammad Safiqul Islam and Ashraful 
Islam S.M. Development and validation of RP-HPLC method for the simultaneous 
estimation of Domperidone and Naproxen in tablet dosage form, Journal of Applied 
Pharmaceutical Sciences, 2011, 1(7). 
41. Sohan S. Chitlange., Amir I. mulla., Ganesh R. pawbake. and Sagar B. Wankhede. 
Simultaneous spectrophotometric estimation of DexRabeprazole and Domperidone 
in capsule dosage form, International Journal of Pharmaceutical Quality 
Assurance, 2010, 2(2), 31-34. 
42.  Sumitra M., Shanmuga sundaram P., Srinivasulu K. Reported Analytical method 
development and validation of Lafutidine in tablet dosage form by RP-HPLC, 
International Journal of Chemtech Research, 2011, 3(3), 1403-1407. 
43.  Sivakumar T., Manavalan. and Valliappan K. Development and validation of a        
RP-HPLC method for simultaneous determination of Domperidone and 
Pantoprazole in pharmaceutical dosage forms, Acta Cromatographica, NO 18, 
2007. 
44. Venkatesh P., Hepcy Kalarani D., Ravindra Reddy K. Spectrophotometric method 
for Simultaneous estimation of Paracetamol and  Domperidone in tablet dosage 
form, Research  Journal of Pharmaceutical , Biological and Chemical Sciences, 
1(3), 155. 
45. Vijaya Ratna J., Krishna Chaitanya K., Samson Israel D. Reported RP-HPLC 
Method development and validation of Domperidone Maleate, International 
Journal of Pharmaceutical Research and Development, 2011, 3(4), 61-64. 
 73 
 
46. Wei- Dong Chen., Yan liang., hao li., Ye Xiong Liu., Guang- Jiwang., Lin Xie. 
Reported Simple, sensitive and rapid LC-ESI-MS method for the quantification of 
Lafutidine in human plasma – Application to pharmacokinetic studies, Journal of 
Pharmaceutical and Biomedical Analysis, 2006, 41(1), 256-260. 
47. Willard H. Hobart., Meritt L. Lynne Jr., John A. Dean. and Frank A. Settle. 
Instrumental Methods of Analysis. 7th edition., CBS Publishers and Distributors, 
 New Delhi, 1986, 118, 141, 437, 539.       
48. William Kemp. Organic Spectroscopy. 3rd edn., Palgrave Publishers, New York, 
1996, 258 -259. 
49. YE Xiang-fa., Han peng. Determination of Lafutidine and its tablets by HPLC, 
North West Pharmaceutical Journal, 2003, 6.  
50. Zheng Heng., Hen ya-li., Wang li., Fang shu-Xian. Reported Determination of 
Lafutidine in human plasma by HPLC-MS, The Chinese Journal of Clinical 
Pharmacology, 2008, 24(1), 71-73. 
51. Zheng Yong., Chen Mei., Zhao chun-jing. Determination of Lafutidine in serum 
with RP-HPLC, Journal of Paediatric Pharmacy, 2006, 3(3). 
